



PUBLICATION DU CONSEIL SUPERIEUR DE LA SANTE N° 8651

Les probiotiques et leurs implications pour la santé publique belge

Caractérisation microbiologique

This project aims at taking stock of the methodologies that are suitable for validating the identity, the quality and the safety of probiotic flora (bacteria and yeast) as a food ingredient.

Février 2012

PREFACE

Les présents travaux du CSS ont pour but ultime de décrire l'état actuel des connaissances quant aux méthodologies grâce auxquelles peuvent être caractérisés des souches et produits possédant une action probiotique présumée. Cet avis ne porte pas sur des souches, produits ou technologies spécifiques.

Face à l'évolution rapide des connaissances scientifiques dans ce domaine, le CSS estime opportun d'émettre un document offrant un aperçu des outils pratiques actuellement disponibles pour établir la composition et l'innocuité de ces produits.

L'avis ne constitue en aucun cas une approbation de produits présentés comme possédant une activité probiotique **quant à une éventuelle efficacité clinique dans la prévention ou le traitement de pathologies** («allégations de santé»).

RESUME

Lorsqu'ils sont ingérés en quantités suffisantes, les probiotiques sont censés conférer un ou plusieurs effets bénéfiques établis sur la santé du consommateur. A titre d'ingrédient alimentaire, ils doivent survivre à leur transit par le tube digestif et proliférer dans l'intestin.

En se consacrant à ce projet, le Conseil Supérieur de la Santé (CSS) de Belgique espère pouvoir mettre à la disposition des professionnels de la santé ainsi qu'à celle des autorités compétentes des informations actualisées sur l'état des connaissances quant à la caractérisation microbiologique des micro-organismes vivants concernés (authenticité et sécurité).

Le présent document porte exclusivement sur la caractérisation des probiotiques. Il offre des informations actualisées sur l'état des connaissances quant à la caractérisation microbiologique des organismes vivants concernés (bactéries et levures). L'examen des perspectives en matière de santé liées à l'utilisation des probiotiques (potentiels et en voie de développement), ainsi que les recommandations aux autorités compétentes pourraient être publiés à un stade ultérieur.

Dans le présent avis:

1) La première partie de l'avis consacré aux probiotiques définit les caractéristiques des micro-organismes vivants pouvant être considérés comme des probiotiques et décrit les méthodes phénotypiques et moléculaires pour l'identification correcte des souches et une caractérisation taxonomique suffisamment précise. Au niveau du typage, ce document attire l'attention sur l'importance de la mise en place d'une base de données (détection, nouvelles espèces, etc.). Une série de tableaux offre un aperçu des nouvelles informations disponibles à ce sujet.

2) En ce qui concerne l'évaluation de l'innocuité des probiotiques, l'isolement et la caractérisation taxonomique permettent d'éviter l'inclusion de souches pathogènes. Identifier les risques sanitaires liés à l'usage des probiotiques suppose une bonne identification des souches utilisées.

L'accent est mis sur les problèmes relatifs à la standardisation des méthodes et à l'interprétation des données. La vérification des caractéristiques de la résistance (intrinsèque ou acquise) aux antibiotiques relève d'une importance capitale dans la lutte contre la propagation de la résistance aux antibiotiques. Ce document décrit également une série de méthodes et de moyens sur la base desquels peuvent être interprétées les données. Les micro-organismes concernés ne doivent afficher aucune virulence ou propriété pathogène pouvant provoquer des symptômes cliniques potentiellement très différents et ne se limitant pas à la région gastro-intestinale. Des paramètres tels que l'adhérence, la translocation et la colonisation demeurent au cœur de nombreuses discussions.

3) Enfin, il est important de réaliser un contrôle de qualité approfondi de ces produits « vivants » en les comparant à certains paramètres et en utilisant les méthodes les plus adéquates. En effet, ces conditions doivent être remplies pour pouvoir mettre à profit le biote probiotique au bénéfice de la santé publique.

L'examen des perspectives en matière de santé liées à l'utilisation des probiotiques (potentiels et en voie de développement), ainsi que les recommandations aux autorités compétentes pourraient être publiés à un stade ultérieur.

Keywords

probiotics, typing, risk assessment, quality control, safety assessment.

MeSH terms

Probiotics; Bacterial typing techniques; Risk assessment; Consumer product safety.

CONTENT

1. INTRODUCTION.....	6
2. STRAIN IDENTIFICATION AND TYPING.....	6
2.1. Microbial species used as probiotics for human application.....	8
2.2. Identification	9
2.2.1 <i>Phenotypic approaches for bacterial identification.....</i>	<i>9</i>
2.2.2 <i>Molecular approaches for bacterial identification.....</i>	<i>9</i>
2.2.3 <i>Yeast identification.....</i>	<i>11</i>
2.3. Typing	11
2.3.1 <i>Bacteria</i>	<i>11</i>
2.3.2 <i>Yeasts.....</i>	<i>12</i>
2.4. Tables.....	13
3. SAFETY ASSESSMENT OF PROBIOTICS.....	17
3.1. Introduction.....	17
3.2. Isolation history and taxonomic characterization	18
3.3. Antimicrobial resistance	18
3.4. Virulence/pathogenic properties	20
3.5. Safety parameters "under debate": colonization, adhesion and translocation.....	24
4. QUALITY CONTROL ON FINAL PRODUCTS	26
4.1. Microbial contamination of the final product.....	26
4.2. Microbial composition.....	26
4.3. Microbial concentration and stability	28
4.4. Authenticity	28
4.5. Labelling and claims	29
5. REFERENCES	31
6. COMPOSITION OF THE WORKING GROUP	45

ABBREVIATIONS AND SYMBOLS

ACE-ART: Assessment and Critical Evaluation of Antibiotic Resistance Transferability in Food Chain (EU project)
AFLP: amplified fragment length polymorphism
API: Analytical Profile Index tests
ARDRA: amplified ribosomal DNA restriction analysis
BSAC: British Society for Antimicrobial Therapy
BPW: buffered peptone water
CCFL: Codex Committee on Food Labeling (in Codex Alimentarius)
CCNFSDU: Codex Committee on Nutrition and Foods for Special Dietary Uses (in Codex Alimentarius)
CFU: colony-forming unit
CLSI: Clinical and Laboratory Standards Institute
DGGE: Denaturing Gradient Gel Electrophoresis
DNA: deoxyribonucleic acid
EFFCA: European Food and Feed Cultures Association
EFSA: European Food Safety Authority
EUCAST: European Committee on Antimicrobial Susceptibility Testing
EMBL: European Molecular Biology Laboratory
EHEC: enterohaemorrhagic *E. coli*
EIEC: enteroinvasive *E. coli*
EPEC: enteropathogenic *E. coli*
ETEC: enterotoxigenic *E. coli*
FAO: Food and Agriculture Organization
FISH: fluorescent *in-situ* hybridization
GG (*L. rhamnosus* GG): title of the strain derived from the names of Goldin and Gorbach
GRAS: generally recognized as safe
HBL: Haemolysin BL (from *Bacillus cereus*)
ICU: intensive care units
IDF: International Dairy Federation
ILSI: International Life Sciences Institute
ISO: International Organization for Standardization
ITS: internal transcribed spacer
LAB: lactic acid bacteria
LSM: LAB susceptibility test medium
LSU: large subunit
MIC: minimum inhibitory concentration
NDA: Panel on Dietetic Products, Nutrition and Allergies of the EFSA
NHE: non-hemolytic enterotoxin
NV: non-viable
NWT: non-wild-type (member of a species)
PCR: polymerase chain reaction
PROSAFE: Product Safety Enforcement Forum of Europe
QPS: qualified presumption of safety
RAPD: randomly amplified polymorphic DNA
RDP: Ribosomal Database Project
RFLP: restriction fragment length polymorphism
RNA: ribonucleic acid
PAI: pathogenicity island
SCAN: Scientific Committee on Animal Nutrition (EU)

SHC: Belgian Superior Health Council
SPF: specific pathogen free
ST: sequence type
STEC: Shiga-toxin-producing *E. coli*
VBNC: viable but non cultivable
VC: viable and cultivable
WHO: World Health Organization
WT: wild-type (member of a species)

1. INTRODUCTION

Le terme « probiotique » est relativement récent et signifie « pour la vie » (du Grec *προ βίος, pro bios*). Metchnikoff (1907) et Tissier (1906) ont été les premiers à avancer dans leurs travaux des suggestions scientifiques quant à l'utilisation probiotique des bactéries, même si le mot « probiotique » ne fut forgé qu'en 1960 pour désigner des substances produites par des micro-organismes et qui stimulent la croissance d'autres micro-organismes (Lilly and Stillwell, 1965). D'autres définitions ont suivi, dont celle de Fuller (1989), qui était la première à souligner la nature microbienne des probiotiques en redéfinissant le mot « probiotique » comme « un complément nutritionnel microbien vivant qui a un effet positif sur l'animal hôte en améliorant son équilibre intestinal ». Havenaar et Huis in 't Veld (1992) ont élargi cette définition comme suit : « une culture viable composée d'une ou d'un mélange de bactéries qui, lorsqu'elle est appliquée à l'animal ou à l'homme, exerce un effet bénéfique sur l'hôte en améliorant les propriétés de la flore indigène ». Plus récemment, Guarner et Schaafsma (1998) ont défini les probiotiques comme des « micro-organismes vivants, qui lorsqu'ils sont consommés en quantités adéquates, ont un effet bénéfique sur la santé de l'hôte ».

La Consultation mixte d'Experts de la FAO/OMS sur l'Evaluation des Propriétés sanitaires et nutritionnelles des Probiotiques dans les Aliments, y compris le Lait en Poudre contenant des Bactéries lactiques vivantes, qui s'est tenue à Córdoba (Argentine), du 1^{er} au 4 octobre 2001, a redéfini les probiotiques dans le cadre de la conférence comme suit : « **Des micro-organismes vivants qui, lorsqu'ils sont administrés en quantités adéquates, exercent une action bénéfique sur la santé de l'hôte** » (FAO/OMS, 2001). A l'instar de la définition de la FAO/OMS, l'International Life Sciences Institute (ILSI, 2002) ainsi que l'European Food and Feed Cultures Association (EFFCA, 2003) ont formulé des définitions similaires pour les probiotiques, à savoir, respectivement, celle d' « ingrédients alimentaires microbiens vivants qui, lorsqu'ils sont ingérés en quantités suffisantes, sont salutaires pour la santé des consommateurs » et « des micro-organismes vivants qui, lorsqu'ils sont ingérés ou appliqués localement en quantités suffisantes, confèrent un ou plusieurs effets bénéfiques établis sur la santé du consommateur ».

La consultation d'experts de la FAO/OMS a limité le cadre des discussions aux probiotiques « dans les aliments », tout en excluant la référence aux agents biothérapeutiques et aux micro-organismes bénéfiques non utilisés dans les aliments. Il est toutefois admis que la définition est suffisamment vaste pour englober toute une gamme de préparations probiotiques et usages escomptés. Dans ce contexte, un probiotique peut être un aliment ou un complément alimentaire, il peut être utilisé dans une application médicamenteuse (également appelée biothérapeutique vivant) ou aliment microbien ou encore comme micro-organisme génétiquement modifié ou vaccin vivant lorsqu'il est administré par la voie orale.

En ce qui concerne leur utilisation dans les aliments, des critères importants ont été documentés pour les probiotiques, et notamment qu'ils doivent non seulement être capables de survivre au transit par le tube digestif, grâce à leur résistance à l'action de l'acide gastrique, de la bile et des enzymes digestives, mais ils doivent également avoir la capacité à proliférer dans les intestins. Les probiotiques doivent pouvoir conférer leurs bienfaits à l'hôte grâce à leur croissance et/ou activité dans le corps humain. Par conséquent, la capacité à rester viable au site cible et à être efficace doit être vérifiée pour chaque souche.

En 2002 (Londres, Canada), un groupe de travail mixte FAO/OMS a élaboré des lignes directrices pour l'évaluation des probiotiques dans les aliments (FAO/OMS 2002). Celles-ci préconisaient l'adoption officielle de la définition des probiotiques ci-dessus de la FAO/OMS et l'implémentation des lignes directrices énoncées dans le rapport de ce groupe de travail à titre de condition préalable pour qu'une souche microbienne puisse être considérée comme un « probiotique ». Parmi les exigences minimales requises pour le statut probiotique figurent :

- l'évaluation de l'identité de la souche (au niveau du genre, de l'espèce, de la souche) ;

- des tests *in vitro* pour analyser les souches probiotiques éventuelles : par exemple pour vérifier leur résistance à l'acidité gastrique, aux acides biliaires et aux enzymes digestives, leur activité antimicrobienne contre des bactéries potentiellement pathogènes, etc. ;
- une évaluation de la sécurité: exigences en matière de présentation des preuves quant à l'innocuité et l'absence de contamination d'une souche probiotique dans sa forme de livraison ;
- des études *in vivo* permettant d'étayer les effets sur la santé de l'hôte cible.

Le groupe de travail a recommandé que les informations accumulées pour démontrer qu'une souche est un probiotique, y compris les preuves obtenues dans le cadre d'un essai clinique, soient publiées dans des revues scientifiques ou médicales soumises à l'examen de pairs. En outre, la publication des résultats négatifs est encouragée, et ce afin de contribuer à l'ensemble des preuves étayant l'efficacité des probiotiques.

Les recommandations de la consultation de la FAO/OMS mentionnée ci-dessus et les lignes directrices du groupe de travail de la FAO/OMS ont été réunies en un seul document (FAO/OMS, 2006) et ont été présentées à deux Comités du Codex Alimentarius: le Comité du Codex sur l'étiquetage des denrées alimentaires (CCFL) et le Comité du Codex sur la nutrition et les aliments diététiques ou de régime (CCNFSDU). L'espoir est que les travaux des groupes « probiotiques » de la FAO/OMS serviront de modèle pour les futures lignes directrices du Codex.

En ce qui concerne les preuves apportées à l'appui des effets bénéfiques des probiotiques pour la santé de l'hôte cible, il est important de savoir qu'en Union européenne, l'utilisation des allégations de santé ne devrait être autorisée qu'après une évaluation scientifique répondant à la norme la plus élevée possible réalisée par le groupe scientifique sur les produits diététiques, la nutrition et les allergies (NDA) de l'Autorité européenne de sécurité des aliments (EFSA) [Règlement (CE) N° 1924/2006]. Voici les questions clés adressées par le groupe NDA de l'EFSA :

- l'aliment/le composant alimentaire a-t-il été suffisamment défini et caractérisé?
- l'effet allégué a-t-il été suffisamment défini, et s'agit-il d'un effet physiologique bénéfique?
- des études pertinentes impliquant des êtres humains ont-elles été présentées pour justifier l'allégation?

Si, à l'issue de toutes les questions énumérées ci-dessus, le résultat est favorable, le groupe procédera à la pondération des preuves apportées par l'ensemble des études pertinentes présentées, y compris celles impliquant des êtres humains, des animaux, celles réalisées *in vitro* et les études mécanistiques.

Le groupe NDA a fourni des lignes directrices générales quant à l'évaluation scientifique des allégations de santé relatives à la fonction intestinale et immunitaire (EFSA NDA 2011). Ces lignes directrices sont particulièrement intéressantes pour les probiotiques, pour lesquels de tels effets sur la santé sont généralement attendus. Ces lignes directrices ne se veulent pas une liste exhaustive des effets bénéfiques et des études/mesures de résultats acceptables, mais plutôt des exemples tirés d'évaluations existantes dans le but d'illustrer l'approche du groupe.

Enfin, il convient de souligner que, outre l'identification et la caractérisation des souches, leur survie au transit par l'appareil gastro-intestinal supérieur, une adhérence transitoire à l'épithélium intestinal ou une interaction avec celui-ci, une colonisation du côlon ainsi qu'une résistance des souches au traitement technologique et au stockage relèvent de la plus grande importance. Ces constats mettent en évidence l'importance de la matrice alimentaire et du processus technologique appliqué pour préparer les aliments (ou composants alimentaires) ainsi que les exigences en matière de stabilité et de survie de la souche jusqu'à la consommation des aliments. Il en ressort, respectivement, une dépendance de la matrice alimentaire (y compris de la quantité d'aliments à consommer pour obtenir un effet sur la santé établi) et l'importance d'une quantité suffisante de cellules actives vivantes.

Compte tenu de l'évolution rapide des connaissances dans ce domaine, cette première partie de l'avis sur les probiotiques offre des informations actualisées quant à l'état des connaissances sur la caractérisation microbiologique des micro-organismes vivants concernés (bactéries et levures). L'examen des perspectives en matière de santé liées à l'utilisation des probiotiques (potentiels et en voie de développement), ainsi que les recommandations aux autorités compétentes seront publiés à un stade ultérieur (partie 2).

2. STRAIN IDENTIFICATION AND TYPING

2.1. Microbial species used as probiotics for human application

A wide range of product types containing viable or heat-killed microorganisms with probiotic claims are commercially available either as fermented food commodities, foods with probiotic ingredients, or in lyophilised form. In accordance to the widely used FAO/WHO definition of probiotics (FAO/WHO, 2001), this chapter will only deal with the identification and typing of live microorganisms used as probiotics for human applications.

With the emphasis mainly on fermented dairy products, a steadily increasing range of yogurt-like products is available on the European market. Probiotic strains used in these products are generally, but not exclusively, derived from the gastrointestinal tract of presumed healthy humans. This is reflected by the high frequency in which strains of autochthonous *Lactobacillus* and *Bifidobacterium* species are applied in these products (Holzapfel *et al.*, 1998; 2001; Klein *et al.*, 1998; Sanders *et al.*, 2003; **Table 1**). *Lactobacillus* is a member of the lactic acid bacteria (LAB) and is naturally occurring on raw food and feed materials but is also a member of the intestinal tract of most mammals. Although also a lactic acid producing bacterium, *Bifidobacterium* is not considered a typical member of the LAB, due to its remote phylogenetic position. To a lesser extent, also other LAB strains belonging to genera such as *Enterococcus*, *Lactococcus* and *Pediococcus* are used as probiotics for humans mainly in dairy-based products. In contrast, strains of non-LAB bacteria such as *Bacillus*, *Propionibacterium* and *Escherichia coli* used as probiotic are rarely included in dairy or other food commodities, but are usually applied as lyophilised or encapsulated pharmaceutical preparations. The use of yeasts in commercial probiotic products is virtually restricted to a single strain commonly referred to as *Saccharomyces cerevisiae* var. *bouardii* (Czerucka *et al.*, 2007), although also other non-pathogenic yeast strains have been the subject of probiotic studies (Foligné *et al.*, 2010).

Importantly, not all microorganisms present in a probiotic product per definition have probiotic characteristics. A typical example is the case of strains of the yogurt starters *Lactobacillus delbrueckii* subsp. *bulgaricus* and *Streptococcus thermophilus*, which are applied mainly for technical reasons but are not commonly regarded as probiotics. The latter point is still under debate as literature searches have shown that viable yogurt starter cultures have the potential to improve lactose digestion and eliminate symptoms of lactose intolerance (Guarner *et al.*, 2005).

The relevance of reliable identification and typing of strains used in probiotic applications is still increasing because of two main reasons. Firstly, it is clear that the use of probiotic strains is no longer strictly restricted to food applications where history of safe use in (traditional) fermented foods was an important argument to neglect the importance of correct classification of probiotics. In recent years, however, probiotics are also more and more used in biotherapeutic and pharmaceutical applications, which are aimed at specific patient groups each with their own clinical risk profiles. As a part of the biosafety evaluation in the course of this type of clinical interventions, it is now commonly accepted that correct identification to the species level and even to the strain level is essential. Secondly, probiotic use no longer only involves monocultures but has meanwhile also witnessed the introduction of several mixed-strain formulations in food products with health-promoting claims as well as in therapeutic trials and applications.

As part of any health claim dossier, it is clear that the individual strains composing such mixtures need to be fully characterized taxonomically.

2.2. Identification

At present, the inappropriate use of identification methods is regarded as the major cause of incorrect species designations of probiotic strains (Huys *et al.*, 2006) and mislabelling of probiotic products (Duc *et al.*, 2004; Masco *et al.*, 2005; Temmerman *et al.*, 2003). Inconsistencies in the microbial identification of commercial products with probiotic claims affects their potential efficacy and safety record, and are likely to have a negative impact on consumer trust.

2.2.1 Phenotypic approaches for bacterial identification

For identification of probiotic bacterial strains, phenotypic tests or commercial miniaturized identification systems such as Analytical Profile Index tests (API) are inadequate for species level resolution. In fact, it is recommended that biochemical characterization should not be used as a stand-alone approach for identification of any probiotic culture. Commercial identification systems may be useful to obtain a first tentative classification at the genus level in conjunction with primary phenotypic tests, but the identification result should in any case be confirmed by other (molecular) methods. It is important to highlight that the usefulness of (commercial) biochemical systems for identification of probiotic bacterial strains is limited, due to the high intra-specific phenotypic variability observed in many bacterial species, and due to the fact that updates of the identification databases linked to these systems are slow or even missing, are often incomplete, and that species entries are poorly documented without listing the reference strains used (Vankerckhoven *et al.*, 2008).

2.2.2 Molecular approaches for bacterial identification

Despite the event of sequence-based approaches, DNA-DNA reassociation is currently considered as the “gold standard” for delineation and description of new bacterial species, but is impractical in routine identification of bacterial cultures. Other molecular methods are therefore preferred provided that they offer sufficient experimental reproducibility and a proper taxonomic resolution and that they make use of updated and easily available and validated identification databases. The use of molecular approaches for identification of species used in probiotic applications is covered in large detail in several review articles (Holzapfel *et al.*, 1998, 2001; Ward & Roy, 2005).

Sequence analysis of the partial or complete 16S ribosomal ribonucleic acid (rRNA) gene is now commonplace as the first tool to use for the taxonomic positioning of probiotic cultures (Yeung *et al.*, 2002). Next to the universal distribution of this gene in all bacterial species, which avoids the use of group-specific protocols, other obvious advantages of using this and other sequence-based methods include the high-level of data reproducibility and exchangeability. Sequencing is now commonly outsourced to specialised service providers and sequencing centers, often with satisfactory to excellent results. The major bottleneck of the 16S rRNA gene sequencing approach for non-experienced users, however, is the taxonomic interpretation of the sequence data by comparison with public sequence databases such as European Molecular Biology Laboratory (EMBL <http://www.ebi.ac.uk/embl/>) and GenBank (<http://www.ncbi.nlm.nih.gov/genbank/>). These databases often contain loads of unreliable, poorly documented, or incomplete sequence entries, which may compromise the accuracy of the identification result. Therefore, experienced users will have to make sure that only validated and complete 16S rRNA gene sequences are used for identification purposes and that full 16S rRNA gene sequences of multiple taxonomic reference strains per taxon (certainly including the type strain) are included in the identification database to encompass the genomic variation within the taxon. The Ribosomal Database Project (RDP; <http://rdp.cme.msu.edu/>) and the Silva rRNA database project (<http://www.arb-silva.de/>) are two

free web-based applications that provide ribosome-related data and services to the scientific community, including online data analysis and aligned and annotated 16S rRNA gene sequences.

In addition to their use for straightforward identification of pure cultures, ribosomal sequences have also been exploited for culture-independent detection of probiotic microorganisms. The use of rRNA-targeted probes provides a unique insight into the dynamics of probiotic microorganisms in complex microbial communities. Nucleic acid probes have been designed to specifically target taxonomic groups at different levels of specificity (from genus to strain). The review by Ben Amor and co-workers (2007) presents a good overview of the currently available and validated 16S rRNA-targeted oligonucleotide probes for the identification of LAB ranging from group and genus to species and subspecies level.

Despite its obvious advantages, it has been shown that 16S rDNA sequencing has a limited resolution for the discrimination of very closely related species, including those which are frequently used in probiotic foods and preparations. Within the genus *Lactobacillus*, for example, some species of the *Lactobacillus delbrueckii* group, the *Lactobacillus casei* group, and the *Lactobacillus plantarum* group are difficult to separate even when using full 16S rRNA gene sequences (Klein *et al.*, 1998; Torriani *et al.*, 2001). In the case the probiotic strain belongs to one of these species, results of 16S rRNA gene sequence identification may only be reliable at the genus level and need to be complemented by other molecular methods to obtain classification at (sub)species level (Huys *et al.*, 2006). To this end, a series of fingerprinting methods including repetitive DNA element (rep)-PCR (polymerase chain reaction), amplified fragment length polymorphism (AFLP), amplified ribosomal DNA restriction analysis (ARDRA) and tDNA intergenic spacer PCR (tDNA-PCR) have been evaluated and optimized for species identification of most probiotic microorganisms (**Table 2**). In contrast to sequence-based approaches, however, fingerprint data are much less exchangeable and reproducible between laboratories and strongly rely on the availability of an extended and up-to-date database of reference profiles. For this reason, fingerprint-based identifications are best performed in expert labs that use standardized protocols and have access to in-house databases for identification of unknown cultures.

The use of protein-encoding housekeeping genes essentially combines the technological advantages of 16S rRNA gene sequencing and the taxonomic resolution of many fingerprinting methods. Sequencing of one or preferably multiple of these genes as taxonomic markers is a crucial step forward in the development of standardised and globally accessible methods for the identification of probiotic cultures. For LAB, the combined sequence analysis of the *atpA*, *pheS* and *rpoA* genes has been successfully explored for species identification of enterococci (Naser *et al.*, 2005), lactobacilli (Naser *et al.*, 2007), leuconostocs (De Bruyne *et al.*, 2007) and pediococci (De Bruyne *et al.*, 2008). Analysis of partial *hsp60* (Zhu *et al.*, 2003) and *rpoB* (Kim *et al.*, 2010) gene sequences have proven to be useful single-locus approaches for the differentiation of *Bifidobacterium* spp. However, concatenation of partial sequences of seven genes (*clpC*, *dnaB*, *dnaG*, *dnaJ1*, *purF*, *rpoC* and *xfp*) may significantly increase the discriminatory power between bifidobacterial species (Ventura *et al.*, 2006). Within the *Bacillus subtilis* group and related taxa, the use of housekeeping genes *gyrB* (Wang *et al.*, 2007) and *rpoB* (Palmisano *et al.*, 2001) is often used for reliable species differentiation.

The most recent insights from whole-genome sequencing have indicated that even conserved genes such as protein-encoding housekeeping genes may be subjected to genomic rearrangements such as deletions, duplications, mutations, recombinations, and lateral gene transfer. This important finding thus suggests that the classification of microorganisms may not be accurately reflected by analyzing the sequences of one gene or a cluster of genes. The current availability of complete genome sequences of thousands of bacterial strains allows to investigate new avenues for bacterial phylogeny and identification. Within the LAB and *Bifidobacterium* species used as probiotics for human applications, the complete genome sequences of more than 50 strains have been submitted to GenBank (**Table 3**).

To compare whole-genome sequences for taxonomic purposes, the possibilities of supertree construction are currently being exploited. In this approach, the information from hundreds of individual phylogenetic trees, each encompassing a set of orthologous gene families are assembled in one single supertree. Although the advanced bioinformatics tools required for this type of analyses are still being developed and/or under evaluation, it is expected that extraction of taxonomic data from whole genomes will eventually also find its place in the identification of probiotic microorganisms such as LAB.

2.2.3 Yeast identification

Identification and classification of yeasts have traditionally been based on morphological, physiological, and biochemical traits. Various commercial biochemical kits have been developed for rapid yeast identification, but mostly for the clinical market. Currently, different molecular biology techniques are available for identification of yeasts.

A reliable starting point for the identification of probiotic yeasts is the D1/D2 large subunit (LSU) rRNA gene sequence database, which encompasses virtually all known yeast species (Fell *et al.*, 2000). However, due to the fact that some distinct species show low sequence divergence, the use of D1/D2 LSU sequences is often complemented by PCR amplification of repetitive DNA elements (Lieckfeldt *et al.*, 1993) and by determination of additional gene sequences, such as the internal transcribed spacer (ITS) region of the rRNA gene cluster (Scorzetti *et al.*, 2002) or protein-coding genes such as the actin gene (*ACT1*; Daniel & Meyer, 2003), and the mitochondrial cytochrome oxidase 2 (*COX2*) and cobalamin-independent methionine synthase (*MET6*) genes (González *et al.*, 2006).

2.3. Typing

2.3.1 Bacteria

In many cases, it is of high importance to characterize probiotic cultures at the individual strain level, a process generally referred to as typing. Such cases may include screening large microbiological collections for probiotic candidates, monitoring selected candidate strains during *in vitro* and *in vivo* trials, quality control of probiotic products, strain authentication in legal matters and epidemiological surveys.

To a large extent, typing of probiotic microorganisms still relies on the use of molecular methods (Holzapfel *et al.*, 2001). Several fingerprinting methods that have been used for species identification such as (rep)-PCR and AFLP are also suitable as typing methods up to the strain level (**Table 2**). Especially in the case of AFLP, the flexibility in choice of specific restriction enzymes and selective PCR primers allows to test multiple combinations, which can significantly increase the discriminatory power at strain level. Depending on the number of isolates to be processed, the required speed of performance, and the expertise of the user, also randomly amplified polymorphic DNA (RAPD) and pulsed-field gel electrophoresis (PFGE) can be applied for typing of probiotic strains (**Table 2**). RAPD allows fast and reliable comparison of larger sets of isolates in a single PCR run, but often lacks the same level of reproducibility offered by other PCR-based fingerprinting techniques, which is an important prerequisite for database construction. Nevertheless, RAPD is still frequently used to discriminate between probiotic strains (Manan *et al.*, 2009; Ratna Sudha *et al.*, 2010). Together with AFLP, by far the highest resolution at strain level can be achieved by PFGE. Although the latter method can be standardized, it requires a dedicated electrophoretic unit and considerable technical expertise. PFGE fingerprinting has been successfully used to differentiate or track probiotic strains in the genera *Bifidobacterium* (Roy *et al.*, 1996; Grand *et al.*, 2003; Masco *et al.*, 2005), *Lactobacillus* (Coudeyras *et al.*, 2008; Vancanneyt *et al.*, 2006; Wind *et al.*, 2010), and *Bacillus* (De Baets *et al.*, 2009).

In addition to DNA fingerprinting, also sequence-based approaches have been used to discriminate or detect individual probiotic strains. The availability of complete genome sequences of probiotic strains not only broadens our biological knowledge of their functional potential, but also offers a myriad of new possibilities for strain differentiation. Based on internal nucleotide sequences of multiple (usually three to seven) housekeeping genes, several multilocus sequence typing (MLST) schemes have been developed for discrimination between bacterial isolates at the intraspecific level. For each gene, 450-500 bp internal fragments with a maximal number of polymorphisms are selected for amplification and subsequent gene sequence analysis. For each housekeeping gene, the different sequences present within a bacterial species are assigned as distinct alleles and, for each isolate, the alleles at each of the loci define the allelic profile or sequence type (ST). The MLST method has several advantages, including reproducibility and data exchangeability and can be automated to a large extent. While MLST is primarily used to study population structure, evolution and phylogeography of bacterial pathogens (Achtman, 2008), depending on the species it also provides good discriminatory power to differentiate isolates for typing purposes. For bacteria, MLST schemes were first developed for clinically relevant microorganisms such as *Enterococcus faecium* (Homan *et al.*, 2002; <http://efaecium.mlst.net>) and *Bacillus cereus* (Helgason *et al.*, 2004; <http://pubmlst.org/bcereus/>). In recent years, MLST schemes have also been developed for several other species commonly applied as probiotics. MLST schemes relevant for typing of probiotic lactobacilli include those developed for the species *Lb. casei* (Cai *et al.*, 2007; Diancourt *et al.*, 2007), *Lb. plantarum* (de las Rivas *et al.*, 2006), and *Lb. salivarius* (Raftis *et al.*, 2011). Recently, an MLST scheme was made available for the probiotic *Bifidobacterium* species *Bf. animalis*, *Bf. bifidum*, *Bf. breve*, and *Bf. longum* (Delétoile *et al.*, 2010). Similar to the mlst.net database for bacterial pathogens, MLST sequence type databases have been launched, for example, for *Lb. casei* (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Lcasei.html>) and *Bifidobacterium* (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Bifidobacterium.html>). These public databases allow queries and downloads of allele sequences and allelic STs, provide several database tools and statistics and are also open to additional data on novel strains and species.

In addition to MLST approaches, analysis of whole genome sequences through comparative genomics can be very useful to identify unique gene sequences that allow to discriminate a given probiotic culture from other members of the same species. Such strain-specific target sequences can then be used to detect a given probiotic in complex environments, such as food matrices or fecal samples, without the need for culturing. Instead, culture-independent methods such as fluorescent *in-situ* hybridization (FISH) and real-time PCR are employed for direct detection and enumeration of the target strain in the sample.

2.3.2 Yeasts

Typing of probiotic yeasts has largely been based on intraspecies polymorphisms located in the ITS regions of the ribosomal gene cluster. As an alternative to ITS sequencing, restriction fragment length polymorphism (RFLP) analysis of amplified ITS regions has been used to differentiate *Saccharomyces* yeasts isolated from various commercial probiotic and biotherapeutic products claimed to contain *S. cerevisiae* or '*S. boulardii*' (Mitterdorfer *et al.*, 2002). In the latter study, the ITS-based approach was combined with RAPD and PFGE fingerprinting to differentiate *Saccharomyces cerevisiae* var. *boulardii* strains from other strains in the species. Previously, Baleiras Couto *et al.* (1996) had already suggested that discrimination of individual strains within *S. cerevisiae* is not possible with a single typing technique. In a comparative study with ITS-based approaches, microsatellite DNA polymorphism analysis and retrotransposon Ty917 hybridization analysis were considered to offer the highest discriminatory power to distinguish probiotic and clinical *S. cerevisiae* var. *boulardii* isolates from other clinical *S. cerevisiae* isolates (Posteraro *et al.*, 2005). More recent developments in typing of *S. cerevisiae* strains focus on the design of MLST schemes. So far, the MLST approach has mainly been applied in wine yeast typing but does not seem to offer the same level of resolution as microsatellite analysis (Muñoz *et al.*, 2009).

2.4. Tables

Table 1: Most important microorganisms applied in probiotic products for human use^{a,b,c}

Lactic acid bacteria	Bifidobacterium	Other bacteria	Yeasts
<i>Lactobacillus</i>	<i>Bf. adolescentis</i>	<i>Bacillus</i>	<i>Saccharomyces cerevisiae</i> var. <i>bouardii</i>
<i>Lb. acidophilus</i>	<i>Bf. animalis</i> subsp. <i>lactis</i>	<i>Bc. cereus</i> ^d	<i>Saccharomyces</i> spp.
<i>Lb. casei/paracasei</i>	<i>Bf. bifidum</i>	<i>Bc. coagulans</i>	
<i>Lb. crispatus</i>	<i>Bf. breve</i>	<i>Bc. clausii</i>	
<i>Lb. fermentum</i>	<i>Bf. longum</i> subsp. <i>infantis</i>	<i>Bc. pumilus</i>	
<i>Lb. gallinarum</i>	<i>Bf. longum</i> subsp. <i>longum</i>	<i>Bc. subtilis</i>	
<i>Lb. gasseri</i>		<i>Escherichia coli</i> Nissle 1917 ^d	
<i>Lb. johnsonii</i>		<i>Propionibacterium</i>	
<i>Lb. plantarum</i>		<i>Pr. acidipropionici</i>	
<i>Lb. reuteri</i>		<i>Pr. freudenreichii</i> subsp. <i>shermanii</i>	
<i>Lb. rhamnosus</i>		<i>Pr. jensenii</i> ^d	
<i>Lb. salivarius</i>			
<i>Enterococcus faecium</i> ^d			
<i>Lactococcus lactis</i> subsp. <i>lactis</i>			
<i>Leuconostoc</i>			
<i>Le. citreum</i>			
<i>Le. mesenteroides</i> subsp. <i>cremoris</i>			
<i>Oenococcus oeni</i> ^e			
<i>Pediococcus</i>			
<i>Pd. acidilactici</i>			
<i>Pd. pentosaceus</i>			
<i>Sporolactobacillus inulinus</i> ^d			

^a Adapted and updated from Holzapfel *et al.*, 1998, 2001 and Sanders *et al.*, 2003.

^b Up-to-date nomenclature of species names can be checked via <http://www.bacterio.cict.fr/>

^c Excluded are the yogurt starter cultures *Lactobacillus delbrueckii* subsp. *bulgaricus* and *Streptococcus thermophilus*.

^d Species not included in the 2009 updated EFSA list of biological agents intentionally added to food or feed recommended for qualified presumption of safety.

^e Probiotic properties have been documented in some strains of this species (Foligné *et al.*, 2010), but no applications for human use are currently known.

Table 2: Fingerprinting methods used for identification and/or typing of probiotic microorganisms

Method	LAB	<i>Bifidobacterium</i>	<i>Bacillus</i>	<i>Propionibacterium</i>	<i>Saccharomyces</i>
AFLP	Torriani <i>et al.</i> , 2001 Vancanneyt <i>et al.</i> , 2006				
ARDRA	Chenoll <i>et al.</i> , 2003; Moreira <i>et al.</i> , 2005.	Křížová <i>et al.</i> , 2006; Roy <i>et al.</i> , 2000; Ventura <i>et al.</i> , 2001		Dherbécourt <i>et al.</i> , 2006.	
ITS analysis ^a			Senesi <i>et al.</i> , 2001.	Tilsala-Timisjärvi <i>et al.</i> , 2001	Baleiras Couto <i>et al.</i> , 1996; Mitterdorfer <i>et al.</i> , 2002; Posteraro <i>et al.</i> , 2005.
PFGE	Coudeyras <i>et al.</i> , 2008; Salminen <i>et al.</i> , 2002; Vancanneyt <i>et al.</i> , 2006; Wind <i>et al.</i> , 2010.	Roy <i>et al.</i> , 1996; Grand <i>et al.</i> , 2003; Masco <i>et al.</i> , 2005	De Baets <i>et al.</i> , 2009.		Mitterdorfer <i>et al.</i> , 2002
RAPD	Manan <i>et al.</i> , 2009		Ratna Sudha <i>et al.</i> , 2010.		Baleiras Couto <i>et al.</i> , 1996; Mitterdorfer <i>et al.</i> , 2002.
rep-PCR ^b	Gevers <i>et al.</i> , 2001; Svec <i>et al.</i> , 2005; Huys <i>et al.</i> , 2006; Coudeyras <i>et al.</i> , 2008.	Gómez Zavaglia <i>et al.</i> , 2000; Masco <i>et al.</i> , 2003 ; Ventura <i>et al.</i> , 2003.	Cherif <i>et al.</i> , 2003.		Vassart <i>et al.</i> , 1987; Groenewald <i>et al.</i> , 2008.

^a Includes sequencing and/or restriction analysis of ribosomal ITS elements

^b Targets repetitive elements such as (GTG)₅, ERIC and BOX for bacteria and M13 for yeasts

Table 3: List of complete genome sequences of *Bifidobacterium* and LAB strains used as probiotics for human applications^a

Strain ^b	GenBank Acc. No.	NCBI RefSeq No ^c
<i>Bf. adolescentis</i> ATCC 15703	AP009256.1	NC_008618.1
<i>Bf. animalis</i> subsp. <i>lactis</i> AD011	CP001213.1	NC_011835.1
<i>Bf. animalis</i> subsp. <i>lactis</i> BB-12 ^d	CP001853	
<i>Bf. animalis</i> subsp. <i>lactis</i> B1-04	CP001515.1	NC_012814.1
<i>Bf. animalis</i> subsp. <i>lactis</i> DSM 10140	CP001606.1	NC_012815.1
<i>Bf. animalis</i> subsp. <i>lactis</i> V9	CP001892	
<i>Bf. bifidum</i> PRL2010	CP001840.1	NC_014638.1
<i>Bf. bifidum</i> S17	CP002220.1	NC_014616.1
<i>Bf. longum</i> DJO10A	CP000605.1	NC_010816.1
<i>Bf. longum</i> NCC2705	AE014295.3	NC_004307.2
<i>Bf. longum</i> subsp. <i>infantis</i> ATCC 15697	CP001095.1	NC_011593.1
<i>Bf. longum</i> subsp. <i>longum</i> BBMN68	CP002286.1	NC_014656.1
<i>Bf. longum</i> subsp. <i>longum</i> F8	FP929034	
<i>Bf. longum</i> subsp. <i>longum</i> JDM301	CP002010.1	NC_014169.1
<i>Lb. acidophilus</i> NCFM	CP000033.3	NC_006814.3
<i>Lb. amylovorus</i> GRL 1112	CP002338	
<i>Lb. casei</i> ATCC 334	CP000423.1	NC_008526.1
<i>Lb. casei</i> BL23	FM177140.1	NC_010999.1
<i>Lb. casei</i> str. Zhang	CP001084.1	NC_014334.1
<i>Lb. crispatus</i> ST1	FN692037.1	NC_014106.1
<i>Lb. delbrueckii</i> subsp. <i>bulgaricus</i> ATCC 11842	CR954253.1	NC_008054.1
<i>Lb. delbrueckii</i> subsp. <i>bulgaricus</i> ATCC BAA-365	CP000412.1	NC_008529.1
<i>Lb. delbrueckii</i> subsp. <i>bulgaricus</i> ND02	CP002341.1	NC_014727.1
<i>Lb. fermentum</i> CECT 5716	CP002033	
<i>Lb. fermentum</i> IFO 3956	AP008937.1	NC_010610.1
<i>Lb. gasseri</i> ATCC 33323	CP000413.1	NC_008530.1
<i>Lb. johnsonii</i> FI9785	FN298497.1	NC_013504.1
<i>Lb. johnsonii</i> NCC 533	AE017198.1	NC_005362.1
<i>Lb. plantarum</i> JDM1	CP001617.1	NC_012984.1
<i>Lb. plantarum</i> WCFS1	AL935263.1	NC_004567.1
<i>Lb. plantarum</i> subsp. <i>plantarum</i> ST-III	CP002222.1	NC_014554.1
<i>Lb. reuteri</i> DSM 20016	CP000705.1	NC_009513.1

<i>Lb. reuteri</i> JCM 1112	AP007281.1	NC_010609.1
<i>Lb. rhamnosus</i> GG ^d	FM179322.1	NC_013198.1
<i>Lb. rhamnosus</i> GG ^d	AP011548	
<i>Lb. rhamnosus</i> Lc 705	FM179323.1	NC_013199.1
<i>Lb. salivarius</i> CECT 5713	CP002034	
<i>Lb. salivarius</i> UCC118	CP000233.1	NC_007929.1
<i>Lc. lactis</i> subsp. <i>cremoris</i> MG1363	AM406671.1	NC_009004.1
<i>Lc. lactis</i> subsp. <i>cremoris</i> NZ9000	CP002094	
<i>Lc. lactis</i> subsp. <i>cremoris</i> SK11	CP000425.1	NC_008527.1
<i>Lc. lactis</i> subsp. <i>lactis</i> II1403	AE005176.1	NC_002662.1
<i>Lc. lactis</i> subsp. <i>lactis</i> KF147	CP001834.1	NC_013656.1
<i>Le. citreum</i> KM20	DQ489736.1	NC_010471.1
<i>Le. mesenteroides</i> subsp. <i>mesenteroides</i> ATCC 8293	CP000414.1	NC_008531.1
<i>O. oeni</i> PSU-1	CP000411.1	NC_008528.1
<i>Pd. pentosaceus</i> ATCC 25745	CP000422.1	NC_008525.1
<i>S. thermophilus</i> CNRZ1066	CP000024.1	NC_006449.1
<i>S. thermophilus</i> LMD-9	CP000419.1	NC_008532.1
<i>S. thermophilus</i> LMG 18311	CP000023.1	NC_006448.1
<i>S. thermophilus</i> ND03	CP002340	

^a Considering their importance in yogurt production, strains of *Lb. delbrueckii* subsp. *bulgaricus* and *S. thermophilus* were also included in the table.

^b The species name as mentioned in the Complete Microbial Genomes list of NCBI (<http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi>) is not necessarily in accordance to the current bacterial nomenclature.

^c The Reference Sequence (RefSeq) database of NCBI provides a comprehensive standard dataset that represents sequence information for a species. RefSeq sequences are derived from GenBank records but differ in that each RefSeq is a synthesis of information, not an archived unit of primary research data.

^d Strains used as probiotics.

3. SAFETY ASSESSMENT OF PROBIOTICS

3.1. Introduction

In general, the microorganisms used in the production of food fermentation have a long history of safe use and are often referred to as “food grade” or GRAS (Generally Recognized As Safe) microorganisms (Holzapfel *et al.*, 1998). Hence, this is the case for most LAB and bifidobacteria (Leroy & De Vuyst, 2004; Foulquié Moreno *et al.*, 2006; Wessels *et al.*, 2004). In Europe, the Qualified Presumption of Safety (QPS) concept exists with a list of microorganisms that can be considered safe for use. The microorganisms intended for human use are regulated in the EU in the context of novel food regulation (Regulation (EC) N°258/97; http://ec.europa.eu/food/food/biotechnology/novelfood/index_en.htm). For microorganisms (probiotics) used as additives in animal feed (Regulation (EC) N°1831/2003), official guidelines for their safety assessment have been fixed at EU level by Regulation (EC) N°429/2008.

In recognition of the importance of assuring their safety for human purposes, even among LAB which are generally considered to have a very good safety record, new and existing probiotic strains need to be characterized with respect to a number of safety aspects. Epidemiological surveillance studies are very important to evaluate the risk of probiotics used in a specific population. In general, four types of side effects of probiotics can be distinguished: systemic infections, metabolic and enzymatic effects, immunomodulation and adjuvants and gene transfer. Among these, the most direct safety risk associated with the consumption of microorganisms is infection (e.g. endocarditis), especially in immunocompromised individuals. In general, the risk of infection by probiotic *Lactobacillus* or *Bifidobacterium* strains is similar to the risk of infection by commensal strains, and thus products containing such probiotic strains present a negligible risk to consumers (Ouwehand & Vesterlund, 2003). On the other hand, some strains of other LAB groups such as enterococci are agents of opportunistic infections. Rare cases of infection associated with certain *Lactobacillus* strains have been reported, mostly in immunocompromised patients (Cannon *et al.* 2005). Bifidobacteria are extremely rarely associated with infections (Hata *et al.*, 1988). *Bifidobacterium*-associated infections are most likely caused by bifidobacteria from the patients’ own microbiota (Wang *et al.*, 1996; MacFie *et al.*, 1999). A recent study reported that the administration of the probiotic *E. coli* strain Nissle 1917 to immunocompromised patients may lead to severe adverse effects (Gronbach *et al.*, 2010).

To establish safety guidelines for probiotic microorganisms, a FAO/WHO working group recommended that probiotic strains are characterized by a series of tests including antibiotic resistance, metabolic activities, toxin production, haemolytic activities, infectivity in immunocompromised animal models, side effects in humans, and adverse outcomes in consumers (FAO/WHO, 2002).

Although still under debate, it is generally agreed that probiotic safety aspects should cover the isolation history and species identity of the probiotic culture and provide phenotypic and/or genotypic evidence showing that the culture does not harbour acquired antibiotic resistance traits, putative virulence factors or other pathogenic properties (Sanders *et al.*, 2010; Salminen *et al.*, 1998; Vankerckhoven *et al.*, 2008b). In addition, it has been suggested that translocation, adhesion and colonization may also contribute to the safety dossier of a probiotic strain. However, current problems in method standardization and data interpretation may need to be solved first before the usefulness of these parameters can be truly accepted.

3.2. Isolation history and taxonomic characterization

Although still a matter of debate, it has been suggested that probiotic strains should originate from the species of intended use. One can argue that a probiotic strain originating from the gastrointestinal tract of a healthy human can function better in a similar environment from where it was originally isolated. Although this point of view has been supported by the fact that most current successful strains are indeed of human origin, some animal-derived strains have also shown positive effects on humans.

In addition to documenting its strain history, the first step in (a) microorganism(s) or product being referred to as a probiotic is to identify the microorganism using internationally accepted methodologies, preferably by combining phenotypic and genotypic methods. The practical approaches for accurate determination of species identity of probiotic cultures have been discussed extensively in **Chapter 2**. Correct identification at species level also implies the use of scientifically recognized names and adequate designation of particular strains. The current state of evidence suggests that different strains can possess different features related to different safety risks, implying that it is not possible to identify the specific safety risks associated with a probiotic strain without proper identification. Reliable identification is also necessary to avoid the inclusion of pathogenic microorganisms in probiotic products.

3.3. Antimicrobial resistance

Due to the indiscriminate use of antibiotics in human and veterinary medicine and as animal growth promoters, antibiotic resistance has become an increasingly common characteristic in (food-borne) microorganisms (Threlfall *et al.*, 2000), causing serious problems in treatment of microbial infections. Antibiotic resistance in bacteria may be intrinsic or acquired. Intrinsic resistance is a naturally occurring trait that may be characteristic for a given species or genus, whereas acquired resistance derives either from genetic mutations or acquisition of foreign DNA from other bacteria.

Probiotic strains with non-transmissible antibiotic resistances do not usually confer a safety concern. To some extent, non-transmissible antibiotic resistance might even be a useful property, if the probiotic strain is to be used as a prophylactic agent in the treatment of antibiotic-associated diarrhoea (Charteris *et al.*, 1998a,b).

However, antibiotic resistance linked to transferable plasmids and mobile elements is a different case because of the possibility of resistance spreading to other, potentially more harmful bacteria. In the end, such increases in the dissemination of antibiotic resistance genes can drastically reduce the therapeutic possibilities in infectious diseases. Given the documented presence of antibiotic resistance genes in LAB and the indirect evidence that these genes could be transferred along the food chain (Teuber *et al.* 1999; Gevers *et al.*, 2003; Jacobsen *et al.*, 2007), it is therefore relevant to assess the presence of transferable antibiotic resistances in LAB strains that are or shall be used as probiotics for human consumption, an opinion which is adopted by EFSA (2005). Different expert panels have indicated that strains harbouring transferable antibiotic resistance genes are not suitable for use as probiotics (Salminen *et al.*, 2001; Vankerckhoven *et al.*, 2008). In this context, the specific risks related to each probiotic strain must be carefully identified.

For phenotypic antimicrobial susceptibility testing of bacterial species with clinical relevance such as enterococci, enterobacteria and certain *Bacillus* species, expert committees such as those appointed by the Clinical and Laboratory Standards Institute (CLSI; www.clsi.org/) and the British Society for Antimicrobial Therapy (BSAC; www.bsac.org.uk/) have proposed a series of standardized and harmonized methods that can be easily performed in most routine labs. However, for non-enterococcal LAB and bifidobacteria, which together account for the vast majority of probiotic cultures currently used, no such standards are available from CLSI, BSAC or other committees. As a result, a variety of non-congruent methods and protocols for the determination of antibiotic susceptibilities of non-enterococcal LAB have been reported in the literature using agar

(overlay) disc diffusion, E-test, broth dilution, and agar dilution (Klare *et al.*, 2005). In general, dilution methods and E-test are preferred as reference methods over conventional diffusion-based tests, as the former techniques allow determining minimal inhibitory concentration (MIC) values which provide a more reliable indication of the intrinsic or acquired nature of a given resistance phenotype. However, due to the fact that many non-enterococcal LAB require specific growth conditions in terms of medium acidity and carbohydrate supplementation, conventional media such as Mueller-Hinton (as recommended by CLSI) and Iso-Sensitest agar (as recommended by BSAC) are not suitable for susceptibility testing of probiotic lactobacilli, pediococci, lactococci and bifidobacteria. In the course of the EU project PROSAFE, two new test medium formulations have been developed for antimicrobial susceptibility testing of non-enterococcal LAB (Klare *et al.*, 2005). The resulting LAB Susceptibility test Medium (LSM) consists of a mixture of Iso-Sensitest broth (90%, v/v) and de Man-Rogosa-Sharpe (MRS) broth (10%, v/v), supplemented with 0.3 g/L L-cysteine hydrochloride for bifidobacteria. The use of the LSM formulation has further been substantiated in another EU project, ACE-ART (www.aceart.ne), which resulted in the proposal to use this medium as standard medium for susceptibility testing of lactobacilli and bifidobacteria from food and non-food origin. Recently, the intra- and interlaboratory performance of the LSM medium and related formulations, specifically adapted for MIC testing of bifidobacteria, *Streptococcus thermophilus* and *Lactococcus lactis*, has been positively evaluated in a small-scale harmonization study (Huys *et al.*, 2010). In parallel, a standard operating procedure, based on data from the PROSAFE and ACE-ART projects, has been validated as an official shared standard of ISO/IDF (International Dairy Federation), i.e. ISO 10932:2010 (IDF 223:2010) standard “Milk and Milk Products - Determination of the Minimal Inhibitory Concentration (MIC) of Antibiotics Applicable to Bifidobacteria and Non-Enterococcal Lactic Acid Bacteria (LAB)” (www.iso.org/iso/iso_catalogue/catalogue_tc/catalogue_detail.htm?csnumber=46434).

The interpretation of MIC data in order to decide whether a (potential) probiotic strain harbours an acquired or atypical antibiotic resistance trait highly depends on the availability of epidemiological cut-off values. The European Committee on Antimicrobial Susceptibility Testing (EUCAST; www.eucast.org) has proposed a number of definitions towards a uniform MIC interpretation. A microorganism is either defined as a wild-type (WT) or non-wild-type (NWT) member of a species by the absence or presence, respectively, of acquired and mutational resistance mechanisms to the antimicrobial agent in question. The strain in question is categorised as WT or NWT within a species based on the cut-off values appropriate for that species and determined with a defined phenotypic test system. This cut-off value will not be altered by changing circumstances and WT microorganisms may or may not respond clinically to antimicrobial treatment (www.srga.org/eucastwt/eucastdefinitions.htm). Ideally, cut-off values are defined at the species level, not at the genus level. In this respect, the availability of correct species identification is an important prerequisite to define such species-specific cut-off levels. For a range of *Lactobacillus* species or species groups, including *Lb. delbrueckii* group, *Lb. plantarum*, *Lb. sakei*, *Lb. rhamnosus*, *Lb. paracasei* group, *Lb. reuteri* and *Lb. fermentum*, specific MIC distributions and tentative cut-off values for a range of antibiotics have been summarized by Korhonen and co-workers (2008). Importantly, these data were obtained using a standard protocol that is largely compatible with the experimental procedures outlined in ISO 10932:2010 (IDF 223:2010). Likewise, MIC distribution data for several important bifidobacterial taxa, including *Bf. adolescentis* group, *Bf. longum* group, *Bf. bifidum*, *Bf. catenulatum* group and *Bf. Animalis*, have been published (Mättö *et al.*, 2007).

Probiotic cultures belonging to the NWT population of a species and thus in which phenotypic resistance has been detected may have acquired antibiotic resistance genes located on plasmids or (conjugative) transposons that may be further transmitted to other microorganisms. The other possibility, i.e. that the antibiotic resistance is due to mutations of chromosomal housekeeping genes, represents a neglectable risk of horizontal dissemination. Verification of the presence of antibiotic resistance genes is thus crucial and can be achieved by the use of dedicated PCR assays when a very specific resistance trait is targeted. The majority of acquired resistance genes so far found in (probiotic) LAB and bifidobacteria are those conferring resistance to tetracycline (i.e. *tet*

genes) and erythromycin (i.e. *erm* genes). PCR primers specific for *tet* and *ery* genes are published and have been validated for use in *Lactobacillus* and *Bifidobacterium* (Klare *et al.*, 2007; Masco *et al.*, 2006). In the case that the potential presence of multiple, rare, or silent (i.e. not phenotypically detectable) resistance genes needs to be verified, the use of dedicated microarrays (Kastner *et al.*, 2006; van Hoek *et al.*, 2008) can be recommended.

If the presence of one or multiple resistance genes is verified, the next step in the risk safety assessment could be to check transfer of the gene(s) under experimental conditions (Gevers *et al.*, 2003; Huys *et al.*, 2006). However, failure to demonstrate *in vitro* horizontal gene transfer does not exclude the risk of dissemination of genes. Thus, whilst negative transfer experiments do not provide evidence for the absence of transfer, standardised transfer methods are still required to estimate whether the probability for resistance transfer is low or high. A standardized conjugation protocol has been developed and validated by several laboratories to assess antibiotic resistance transfer between lactococcal species (Lampkowska *et al.*, 2008). However, such protocols still need to be established for *in vitro* transfer experiments with lactobacilli and bifidobacteria.

3.4. Virulence/pathogenic properties

In general, potential probiotic strains should be screened *in vitro* for their interactions with cell lines to investigate possible cytotoxic or cytopathological effects after growth in different media, for the presence of known virulence genes (e.g. lecithinase activity, toxin genes) and for the presence of mobile genetic elements. After these *in vitro* tests for potentially safe use, *in vivo* toxicity tests and persistence studies would be required. A recent study by Hütt *et al.* (2011) shows how to evaluate the *in vivo* safety and persistence of *Lactobacillus* strains in the gastrointestinal tract of healthy adult volunteers after oral consumption of high doses of lactobacilli.

The long history of safe use of probiotic LAB is the best evidence for the safety of probiotic products. *Lactococcus* and *Lactobacillus* are most commonly given the “generally recognized as safe” or GRAS status. Other LAB genera like *Streptococcus* and *Enterococcus* and other genera that could be used as probiotics contain opportunistic pathogens (Gueimonde *et al.*, 2004). The absence of pathogenicity of any potential probiotic strain must be shown to prove its safety.

It should be addressed that in general the number of infections with *Lactobacillus* strains are very low. For instance, the risk of *Lactobacillus* infections is estimated at about one case per 10 million people over a century of probiotic consumption in France (Bernardeau *et al.*, 2006). Even after performing different clinical trials and human studies, including one involving enteral feeding of premature infants with a commercial *Lactobacillus rhamnosus* strain called GG, no pathogenic potential could be indicated (Saxelin, 1997). However, a recent review by Cannon *et al.* (2005) reported all cases of lactobacillemia identified through a Medline search of articles published between 1950 and 2003. From the 241 cases identified, lactobacilli were implicated in endocarditis, bacteremia and localized and other infections. *Lactobacillus casei* and *Lb. rhamnosus* (amongst which a case due to consumption of large quantities of fermented milk with the probiotic strain GG in the months before hospitalisation; Rautio *et al.*, 1999) were the species most commonly responsible for these pathologies. In recent years, some cases of liver and spleen abscesses caused by lactobacilli have been described (Cukovic-Cavka *et al.*, 2006; Chan *et al.*, 2010; Doi *et al.*, 2011). Most of these lactobacillemia cases are associated within the population with a reduced immune function. In a recent comprehensive review on probiotic infections in patients receiving probiotics in conjunction with nutritional support, it appeared that all 20 case reports of adverse events in 32 patients involved infections due to *Lb. rhamnosus* GG or *Saccharomyces boulardii*; the risk factors included central venous catheters and disorders associated with increased bacterial translocation (Whelan and Myers, 2010). The dominance of these two probiotic species in these reported cases may be linked to their wider use in clinical settings rather than their increased virulence. The question if food containing probiotics is at the origin of the endocarditis cases is not clear because *Lactobacillus* isolates from blood cultures and from commercially dairy products are

different based on the carbohydrate fermentation (Saxelin *et al.*, 1996). Another report described the case of a person suffering of a *Lactobacillus* associated endocarditis after having teeth extracted due to caries. The non-gastrointestinal way of consumption is maybe at the origin of this infection (Mackay *et al.*, 1999). But in general, it could be said that the frequency of *Lactobacillus* infective endocarditis is very low, between 0.05 and 0.4% of the total of bacterial endocarditis cases. The results should be handled with care due to false or incomplete identification of the strains in some studies, which highlighted the necessity of molecular tools for strain identification (Lau *et al.*, 2004).

In contrast to *Lactobacillus* spp. the genus *Enterococcus* has a higher potential safety risk, although enterococci are used as starter cultures in the food industry as well as probiotics (Foulquié Moreno *et al.*, 2006; Franz *et al.*, 2011). It is emerging as a major cause of nosocomial infection causing endocarditis, bacteremia, central nervous system infections, neonatal infections, urinary tract infections and other infections, and isolates are increasingly found to carry virulence factors (Choi *et al.*, 2004). The origin of enterococcal pathogenicity is linked to factors involved in adhesion, translocation and immune evasion (Johnson *et al.*, 1994). A multiplex PCR can be used for the detection of the presence of specific enterococcal virulence genes such as *asa1*, *gelE*, *cylA*, *esp* and *hly* (Vankerckhoven *et al.*, 2008). As an example, none of the 12 probiotic *E. faecium* strains tested by this multiplex PCR tested positive for the virulence genes. This multiplex PCR can be used for testing the intrinsic virulence capacity of a strain and, together with other molecular typing methods, it could be an additional criterion in assessing the safety of new potential probiotic *E. faecium* isolates (Vankerckhoven *et al.*, 2008). *Enterococcus faecalis* carries a pathogenicity island (PAI) of 153 kb containing several virulence factors and is, therefore, believed to be more virulent than *E. faecium*, although horizontal transfer of the entire PAI into the chromosome of *E. faecium* has been demonstrated (Gomez *et al.*, 2011; Vancanneyt *et al.*, 2002). *Enterococcus faecium* is mostly used as probiotic like in four commercial tablet products in Japan, although they are mislabelled as containing *E. faecalis* (Hammad and Shimamoto, 2010).

Probiotic *Bacillus* strains are gaining increasing interest because their sporeforming capacity has obvious advantages in relation to stability and viability of the probiotic product when this contains spores instead of vegetative cells (Sanders *et al.*, 2003). Moreover, it has become apparent in recent years that several *Bacillus* species, such as *B. subtilis*, have adapted to a life style in the gastrointestinal tract (Hong *et al.*, 2009). The use of *Bacillus* spores as probiotic implies the direct consumption of high concentrations of viable cells. One of the commercial products produced in Europe and marketed in at least three EU countries (a.o. Belgium), namely Bactisubtil, seems to contain *B. cereus* spores, although the product label originally mentioned *B. subtilis*. The same strain as in Bactisubtil has also been used in the animal feed product Paciflor, which has been withdrawn in 2002 from production due to the ability of the strain to produce diarrhoea enterotoxins HBL (hemolytic enterotoxin complex) and NHE (nonhemolytic enterotoxin). Two other human probiotics produced outside Europe (Biosubtyl and Subtyl in Vietnam and Biovicerin in Brazil) also contain *B. cereus* spores. Strains belonging to the *Bacillus cereus* group are known to be able to cause two kinds of foodborne illness (SHC, 2009). First, there is an emetic (vomiting) illness due to the ingestion of food containing the heat-stable toxin cereulide. The second is a diarrheal infection due to the ingestion of *Bacillus cereus* strains producing heat-labile enterotoxins in the small intestine. Several published PCRs for these virulence genes or toxins could be used to screen *B. cereus* group strains (Wehrle *et al.*, 2009). However, PCR detection of toxin genes is not a definite proof of potential toxin production, which should be looked for in a cytotoxicity test.

Probiotic products can also contain strains of, for example, *B. licheniformis*, *B. clausii*, *B. subtilis* and *B. pumilus*. Although much less important in food-poisoning incidents, strains of several of these *Bacillus* species are also known to be potential producers of heat-stable or heat-labile toxins (e.g. De Jonghe *et al.*, 2010). Because the *B. cereus* toxin PCRs are not valid for these toxins, a cytotoxicity test could be performed to exclude any pathogenic opportunity of the *Bacillus* strain (see references in De Jonghe *et al.*, 2010).

E. coli Nissle strain 1917 is a well-known probiotic strain used in clinical trials to treat ulcerative colitis (e.g. Kruis *et al.*, 2004). Yet, treatment with this strain has also been associated with sepsis such as a case of severe sepsis in a preterm infant (Guenther *et al.*, 2010). Using a mice model, the safety of *E. coli* Nissle strain 1917 was assessed under different conditions of defective immunity and intestinal microbiota (Gronbach *et al.*, 2010). It was found that if both the microbiota and adaptive immunity are defective, the strain may have potentially severe adverse effects. For other *E. coli* strains which would be considered as potential probiotics, it is important to ascertain that they don't belong to one of the pathogenic *E. coli* groups, such as STEC, EHEC, ETEC, EIEC, EPEC, etc. (Nataro and Kaper, 1998). Several multiplex PCRs are described to investigate if an *E. coli* strain contains virulence genes and belongs to one of these pathogenic groups (e.g. Antikainen *et al.*, 2009).

Propionibacteria and bifidobacteria belong both to the coryneform bacteria and are used in (probiotic) dairy products. The safety of these bacteria as dairy microorganisms has been recently reviewed (Meile *et al.*, 2008). In contrast to the cutaneous *Propionibacterium* spp. or the so-called "acnes group", the dairy *Propionibacterium* spp. are regarded as safe and do not carry any known virulence factor, although *P. thoenii* and *P. jensenii* strains show β -haemolytic activity. *Bifidobacterium* is certainly among the safest genera used as probiotics and the risks of healthy consumers being seriously infected by eating dairy products containing bifidobacteria is extremely low. Nevertheless, as bifidobacteria are common members of the human intestinal microbiota, they may behave as opportunistic pathogens like other commensal bacteria and indeed some commensal bifidobacteria have been connected with certain dental infections, pulmonary infections, bacteremia, abscesses and bloodstream infections. The non-probiotic *B. dentium* is the only bifidobacterial species classified as a pathogen.

Saccharomyces boulardii (present in Enterol®) has been associated with cases of fungemia (Enache-Angoulvant & Hennequin, 2005). Several factors constitute excessive and undue risk for development of *Saccharomyces* fungemia during probiotic administration. These factors are the patient's immunocompromised state during critical illness, the potential for live yeast spore contamination of healthcare workers' hands during preparation of the probiotic capsule or sachet for administration, and introduction of live yeast from contaminated hands (even after hand-washing) to catheter sites (Venugopalan *et al.*, 2010).

Currently, probiotics or synbiotics are being used experimentally in patients hospitalized in intensive care units (ICU), so-called critically ill patients, because in these patients significant alterations in the gut microbiota occur which can lead to severe sepsis with associated multisystem organ dysfunction and death. It remains uncertain whether the use of probiotics or synbiotics in these circumstances is beneficial or even dangerous to the clinical outcome. There is a need for well designed multi-center studies with a defined mixture of bacteria on a defined group of critically ill patients before any conclusion can be drawn. In addition, the end-points have to be clearly defined (Jacobi *et al.*, 2011). Recently, it has been concluded from a clinical trial of probiotic prophylaxis in predicted severe acute pancreatitis patients, that probiotic prophylaxis should not be administered in this category of patients because the probiotic preparation used (Ecologic® 641 consisting of six strains of viable and freeze-dried bacteria, namely *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus salivarius*, *Lactococcus lactis*, *Bifidobacterium bifidum* and *Bifidobacterium lactis* in a total daily dose of 10^{10} bacteria) did not reduce the risk of infectious complications and was even associated with an increased risk of mortality (Besselink *et al.*, 2008). Following the publication of this report, several reactions of colleagues appeared amongst which that probiotics should only be contemplated if the integrity of the gastrointestinal tract is not severely compromised (Bjarnason *et al.*, 2008). In a recent comprehensive review on probiotic infections in patients receiving probiotics in conjunction with nutritional support, it appeared that only 3 out of 53 trials, in which 4131 patients received probiotics, showed increased complications, which were largely non-infectious in nature and in specific patient groups (e.g. transplant and pancreatitis) (Whelan and Myers, 2010). The authors recommend preliminary safety trials when a probiotic is to be investigated for the first time

in a patient group receiving nutritional support and that caution should be taken in patients with risk factors for adverse events.

Genome analysis of probiotic strains

With the advent of next generation sequencing techniques, the number of full bacterial genomes being sequenced has increased rapidly. In Table 3, > 50 complete genomes of probiotic strains of bifidobacterial and LAB strains are listed, and > 100 more genomes are being sequenced. Comparative genomics are now being used to find core genes, niche-specific genes and genes linked to specific probiotic traits, but can as well be used to find or exclude virulence or antibiotic resistance genes or to find indications of chromosomal integration of horizontally acquired DNA (e.g. sequence context screening of t_{RNA} genes), which could indicate the potential of horizontal transfer of virulence or resistance genes. For example, from a comparative genomic analysis between a probiotic and a clinical *E. faecalis* strain, it seems that several of the above mentioned enterococcal virulence factors present are absent in the probiotic strain *E. faecalis* Symbioflor I (Domann *et al.*, 2007). Likewise, a genomic comparison between the probiotic strain *E. coli* Nissle 1917 and other *E. coli* strains has indicated the lack of defined virulence factors (i.e. α -hemolysin, P-fimbrial adhesions) in the probiotic strain (Grozdanov *et al.*, 2004), but another study indicated that genetic variations (e.g. mutations) and gene expression differences, rather than genomic content of virulence genes per se, contribute to the divergence in the pathogenic traits between *E. coli* strains (Vejborg *et al.*, 2010).

Metabolic activity (enzymatic activity associated with production of toxic substances)

Another requisite of probiotics is that the probiotic bacteria should not produce harmful substances by metabolic activities. One way to test this is to assess whether the strain converts food components or biological secretions into secondary substances harmful to the host. For example, some intestinal bacteria are known to convert proteins and their digested products into ammonia, indol, phenols and biogenic amines (histamine, tyramine, putrescine, etc.) (Drasar, 1974). There are no real indications on the production of harmful compounds by *Lactobacillus* and *Bifidobacterium* species. However, Araya-Kojima and co-workers (1995, 1996) measured the enzyme activities related to the consumption and generation of ammonia in *Bifidobacterium* species of human origin. Compared with other bacteria of the intestinal microbiota, *Bifidobacterium* species have a lower deaminase activity involved in the production of ammonia from amino acids but a higher ammonia assimilation activity. Secondary bile acids are important harmful substances that are produced by intestinal bacterial actions on body secretions. They may exhibit carcinogenicity by acting on the mucous-secreting cells and promoting their proliferation, or they may act as promoters of carcinogenesis (Cheah, 1990). Many intestinal bacteria, including *Bifidobacterium* and *Lactobacillus* species, can deconjugate conjugated bile acids (Midtvedt & Norman, 1967). However, *Bifidobacterium* spp., *Lactobacillus* spp., *Leuconostoc lactis* subsp. *lactis* and *S. thermophilus* have been reported to lack the 7 α -dehydroxylase activity that is related to the production of secondary bile acids (Takahashi *et al.*, 1994; Ferrari *et al.*, 1980). For *Enterococcus*, cytolytic substance and other virulence factors have been reported (Jett *et al.*, 1994).

Platelet-aggregating activity and mucus degradation activity

Platelet aggregating activity has been considered to be a required test in the assessment of probiotic safety. Aggregation of platelets by bacteria is thought to contribute to the progression of infective endocarditis (Douglas *et al.*, 1990). In this context, Harty and co-workers (1993a) measured the platelet-aggregating activity of strains of *Lb. rhamnosus* and *Lb. paracasei* subsp. *paracasei* isolated from infective endocarditis, laboratory strains of the same species, and strains of the species *Lb. acidophilus*, *Lb. fermentum*, *Lb. oris*, *Lb. plantarum*, and *Lb. salivarius*. The platelet-aggregating activity was shown to be very strain-specific. The aggregation is thought to be associated with the proteins on the outer cell layer. The properties of the outer cell layer have been measured by hydrophobicity, hydroxyapatite adhesion and salivary aggregation. *Lactobacillus rhamnosus* strains isolated from infective endocarditis have higher activities than do laboratory

strains of *Lb. rhamnosus* (Harty *et al.*, 1993b). As for the other virulence factors, the activities of glycosidases and proteases (arylamidase), which might enable the breakdown of human glycoproteins and the synthesis and lysis of human fibrin clots, have been measured in *Lb. rhamnosus*, *Lb. paracasei* subsp. *paracasei* and other strains. Some strains produce these enzymes, suggesting that they may have an infective property in causing endocarditis (Oahey *et al.*, 1995). However, a study that aimed to measure the enzymatic activities relating to degradation of intestinal mucus glycoprotein in several strains of *Lactobacillus* and *Bifidobacterium* found no such activity in these strains (Ruseler-Van Embden *et al.*, 1995). Further research on the structure of the outer cell layer or the above-mentioned enzyme activities in probiotic bacterial strains is expected. Whether the outer layer structure, which contains surface proteins, glycoproteins and lectins, is really related to infectivity and whether glycosidases, proteases (arylamidase) and other enzymes capable of degrading human intestinal cells are related to infection remain to be elucidated.

3.5. Safety parameters “under debate”: colonization, adhesion and translocation

As mentioned above, the QPS list used in Europe describes the microorganisms that can be considered safe for use in food applications. Members on this list often have “a long history of safe use”, without any negative effect mentioned in the literature. The QPS list is based on identification at the **species level**, while it is generally accepted that probiotic effects are **strain-specific**. It is fair to say that also virulence factors are strain-specific and may vary largely within a species. As an example, *Escherichia coli* is often mentioned.

This species comprises harmless commensal strains, which we all carry with us without any problem, but pathogenic strains which are, for instance, enteroinvasive (EIEC;

www.fda.gov/Food/FoodSafety/FoodborneIllness/FoodborneIllnessFoodbornePathogensNaturalToxins/BadBugBook/ucm071298.htm) or enterohaemorrhagic (EHEC;

www.fda.gov/food/foodsafety/foodborneillness/foodborneillnessfoodbornepathogensnaturalttoxins/badbugbook/ucm071284.htm) are widely known and studied. Underlying mechanisms for invasiveness and pathogenicity are gradually being understood, although many uncertainties remain.

In the process of infection and invasion, three aspects may be important: a first contact or adhesion between the bacterial strains and the epithelial cells, a further translocation of the strain into or through the intestinal epithelium and proliferation in the sterile body site, either at the level of the lamina propria, the mesenteric lymph nodes or systemically (Berg, 1992; Dietch *et al.*, 1992), leading to sepsis, endocarditis and bacteremia (Steinberg 2003). For this reason, it has been suggested that the **adhesion** and **translocation** potential of a strain should be considered as part of the safety evaluation of probiotics (Salminen & Marteau, 1997).

Adhesion has been considered as a possible probiotic characteristic, since adhesion can prolong the intestinal colonization of the probiotic strain, improve the beneficial immune interactions, occupy receptors that could otherwise also “accommodate” pathogens and fortify the intestinal barrier. Clearly, the subject is controversial and further research into the many factors that may influence the outcome of adhesion tests is required. Different tests, different epithelial cell lines, whether or not mucus was included, or simply different laboratories all seem to result in different findings. In addition, also the physiological status of the bacteria seems to matter and, consequently, many doubts exist on the value of *in vitro* tests to predict the *in vivo* effect of a particular strain. Adhesion may also depend on the local competition with the commensal microbiota, on the number of bacteria consumed, and above all, eventual translocation will heavily depend on the immune status of the hosts. Effects of translocated bacteria may also be very different.

The way to deal with this is far from clear. The absence of pathogenicity and infectivity is a prerequisite of probiotic safety. The isolation of LAB or bifidobacteria from clinical cases, however, is likely to be the result of opportunistic infections (Adams & Marteau, 1995; Donohue & Salminen, 1996; Klein *et al.*, 1992). To some extent, the increasing isolation rate from these infections may

be due to an increased awareness of the role of these bacteria in opportunistic infections, or may result from the use of improved identification methods. A sensible approach in studying this would be to consider the question whether invasion of the host by the bacteria leads to infection and whether infection results in a severe outcome (Ishibashi & Yamazaki, 2001).

In this approach, **translocation** is probably a much more important phenomenon than adhesion, as adhesion without translocation is rarely a problem and could, as argued above, even be beneficial. Systemic infection by intestinal bacteria after translocation is a cause of opportunistic infection in immunocompromised hosts (Sedman *et al.*, 1994; Wells *et al.*, 1992) and may be linked to intestinal mucosal injury, immunodeficiency of the host or bacterial overgrowth (Ishibashi & Yamazaki, 2001; Berg *et al.*, 1988; Deitch *et al.*, 1985).

“Infective” bacterial translocation from the intestine is difficult to induce in healthy animals (Berg 1980; Daniel *et al.*, 2006), although “controlled” bacterial translocation can be seen as a highly regulated, physiological event that occurs continuously in healthy subjects at a low rate (Daniel *et al.*, 2006). When the integrity of the intestinal barrier is disturbed or when the immune system is not able to confine an infection, pathogenic or commensal bacteria can reach the bloodstream and cause septicemia (Berg, 1999). Therefore, antibiotic treatment, administration of immunosuppressive agents, or induction of colitis are used to measure bacterial translocation (Salminen & Marteau, 1997; Berg, 1983; Daniel *et al.*, 2006). While bacterial translocation does not occur easily in healthy specific pathogen free (SPF) animals, it is known to occur for a long duration in germ-free mice (Ishibashi and Yamazaki, 2001; Berg and Garlington, 1979; Maejima and Tajima, 1973), linked to the immature intestinal barrier and the underdeveloped immune system of these germ-free animals (Deitch *et al.*, 1991; Foo & Lee, 1972).

Assessment of the safety of probiotics from various angles is not a simple task (Ishibashi and Yamazaki, 2001). The test item that has been attracting attention is whether the bacteria possess infectivity. Assessment of the ability to cause opportunistic infection is difficult. The acute and chronic toxicity tests probably provide circumstantial evidence. However, observations of the passage of bacteria across the intestinal barrier and invasion of the host body by translocation provide more direct data for determining infectivity.

4. QUALITY CONTROL ON FINAL PRODUCTS

4.1. Microbial contamination of the final product

Probiotic foods have steadily gained popularity over the past decades and a wide variety of foods nowadays contain probiotic cultures.

Strains are selected based on their specific health-promoting effects, but it is obvious that the safety aspects are also carefully considered to ensure that they do not pose any health risk for the consumer. The safety evaluation usually includes screening for (transferable) antibiotic resistance genes, virulence or pathogenic properties, undesirable metabolic activities and collecting of evidence to demonstrate a “history of safe use”, etc. (Salminen *et al.*, 1998). Once a strain has been approved, it must still be determined whether the analytical methods that are normally used to verify the microbiological safety of the ingredients and the finished products can also be used for the product with the probiotic strains. For microbiological methods, this is not very obvious: finished products typically contain ca. 7 to 8 log cfu/g and the initial starter may contain more than 11 log cfu/g and it should be taken into account that the presence of undesirable contaminants is masked by the abundance of the beneficial microorganisms.

Theoretically, this problem is most likely to occur with non-selective cultural methods. However, even with selective methods this possibility should be considered, in particular because many of these methods include a non-selective pre-enrichment step. This is, for instance, the case for various internationally recognized protocols, for example for the isolation and detection of *Salmonella* (ISO standard 6579:2002).

A study performed by Joosten *et al.* (2006) clearly demonstrated that false-negative results could be obtained for the detection of *Salmonella* in infant powder with probiotics. The high incidence of false-negative results can probably be explained by the metabolic activities, properties of the probiotic bacteria, in particular the production of organic acids, whose accumulation could render the pre-enrichment broth into a hostile environment for *Salmonella*. By using double strength buffered peptone water (BPW) supplemented with vancomycin (10 µg/ml) and malachite green (100 µg/ml) and non-fat dry milk powder (10 g/l) as pre-enrichment medium, the recovery of *Salmonella* was much better (Joosten *et al.*, 2006). For the detection of other pathogenic bacteria, especially when a non-selective enrichment is used, a similar problem could be observed. By adding antimicrobial compounds to selectively suppress the growth and/or metabolic activity of the probiotic bacteria this problem could be resolved. But more research is needed to optimise the enrichment procedures.

For the enumeration of the total microbiota, especially the contaminating microbiota (without the enumeration of the probiotic strain), the addition of 2 % sodium phosphate or 5 % glycerophosphate could solve the problem (Champagne *et al.*, 2009). To study more in detail the problem of detection of contaminants in starter cultures and probiotics, a specific ISO working group started in 2010 (ISO/TC 34/SC9).

4.2. Microbial composition

Several research labs have independently analyzed the microbial composition of probiotic dairy products (Reuter, 1997; Masco *et al.*, 2005; Holzapfel *et al.*, 1998; Hamilton-Miller *et al.*, 1999; Temmerman *et al.*, 2003a,b). The overall conclusion from these studies is that a considerable number of dried food supplements and - although to a much lesser extent - dairy products are incorrectly or inadequately labeled, with regard to the correct identity of the incorporated probiotic strains. At a time when consumers become more and more aware of the important link between nutrition and health, it is thus of paramount importance that probiotic products with claimed health-promoting effects are well-controlled regarding their microbial composition.

Ideally, microbial analysis of probiotic products relies on standardized and accurate procedures for both the isolation and the identification of the implemented strains. In practice, however, microbial quality control of probiotic products is carried out using a culture-dependent or a culture-independent approach, or a combination of both, with each of these approaches having specific drawbacks and limitations. Especially in the case of multispecies products, a reliable taxonomic inventory may be difficult to achieve.

In a culture-dependent approach, the most crucial step is the recovery of the probiotic strain(s) from the product matrix, using one or more selective isolation media (Schillinger, 1999; Coeuret *et al.*, 2004). Some probiotic strains are the result of isolation campaigns that employed very specific growth conditions which are not always provided by commercial media or by the standard set of incubation parameters used for isolation. In this context, it has been shown that especially *Bifidobacterium* strains may be hard to recover from the original products, and that selective isolation of bifidobacteria from products which also contain LAB is not always straightforward (Temmerman *et al.*, 2003a; Masco *et al.*, 2005). Although still far from optimal, improved protocols and selective media with a higher performance have been proposed for specific enumeration and isolation of bifidobacteria from (probiotic) samples (Roy, 2001; Masco *et al.*, 2005).

After isolation, a limited number of colonies are usually subjected to taxonomic characterization for the purpose of species identification as described in **Chapter 2**. When the most optimal isolation conditions were applied but culture-dependent analyses are negative, it can be concluded that the targeted bacteria are either absent or are present in numbers beneath 1000 cfu/ml or cfu/g, which is generally considered to be the detection limit of culture-dependent analyses.

In order to circumvent the possible pitfalls of conventional culturing, culture-independent methods are increasingly being used for both qualitative and quantitative microbial analysis of probiotic products, because it may overcome some of the major disadvantages or limitations of culture-dependent approaches in terms of speed, taxonomic resolution and reproducibility. Denaturing gradient gel electrophoresis (DGGE) is a DNA fingerprinting technique that has been widely used to unravel the microbiological composition of commercial probiotic products (Ercolini, 2003; Temmerman *et al.*, 2003b; Fasoli *et al.*, 2003; Masco *et al.*, 2005; Theunissen *et al.*, 2005). Essentially, the DGGE method relies on (i) the isolation of total genomic DNA from the probiotic product, (ii) the selective amplification of a hypervariable region of the 16S rRNA gene by community PCR, and (iii) the electrophoretic separation of the resulting pool of PCR amplicons based on sequence content using DGGE (Huys *et al.*, 2008). In theory, the resulting DGGE fingerprint will visualize all species present in a given probiotic product by a unique band, which can be identified by band position analysis, band sequencing and/or band hybridization. Despite the simplicity of its methodological concept, however, the interpretation of a DGGE fingerprint requires specific expertise, as some band positions may coincide with those of other phylogenetically closely related bacteria, some species may be represented by multiple bands due to the so-called 16S rDNA multi-operon effect, or species present in numbers beyond the detection level may not be visible (Huys *et al.*, 2008). To improve the detection capacity of DGGE, group-specific primers can be used (Huys *et al.*, 2008).

Whereas DGGE has been successfully used to determine the microbiological composition of probiotic products, it does not provide a lot of information regarding the relative number of each species present. As discussed in **Chapter 2**, a range of validated 16S rRNA-targeted oligonucleotide probes is available for the identification of LAB ranging from group and genus to species and subspecies level (Ben Amor *et al.*, 2007). Commonly, these probe sequences are converted to genus-, species- or strain-specific PCR primers in the design of real-time quantitative PCR assays to assess the relative concentration of the constituting strains and species in a given probiotic product (Vitali *et al.*, 2003; Furet *et al.*, 2004; Masco *et al.*, 2007).

4.3. Microbial concentration and stability

The quality of a microbiological product, such as a starter or more generally a powder enriched with microbial cells, is generally quantified by its content in microbial cells, and among these cells two properties being expected: the ability to divide and to display a metabolic activity when introduced in a medium or a food composition. These properties are generally represented by a term called viability. However, recent studies have shown that cell division and metabolic activity are not always correlated, since microbial cells are able to reach a transient state where no cell division occurs but metabolic activity is maintained (Booth, 2002), leading to a distinction between viability (or ability to divide) and vitality (related to the metabolic activity). These observations have led to the distinction between three classes: viable and cultivable (VC), non-viable (NV) and viable but non cultivable (VBNC). This last class has been the subject of intensive studies followed by the development of a dedicated method in order to make the distinction between VC, NV and VBNC states (Lowder, 2000). Traditional microbiological methods rely on direct counting of microbial cells either by microscopy or by plate counting. The second method is generally preferred, since it gives directly the amount of cells able to divide with a result being expressed as “colony forming units”. However, this method presents several drawbacks: it is labor intensive, it is subjected to variability and it is not able to display the VBNC state. The emergence of fluorescence-based techniques has led to a great improvement of the understanding of microbial viability and its evolution throughout processes (Breeuwer, 2000). The use of specific fluorescent dyes allows to get a strong insight into the level of the intracellular structures in relation with cell viability. The most used techniques involve stains displaying different behaviors related to membrane permeability and/or degree of damage. The combination of fluorescent-based techniques with high-throughput experimental techniques has led to new opportunities in order to improve the analytical tools dedicated to the determination of the cellular properties (Müller, 2010). In this area, flow cytometry is an emerging technology in the field of food, environmental and industrial biotechnology for the assessment of microbial viability (Berney, 2007). The main advantage of this method is that it does not require a cultivation step of the microorganisms before analysis. Indeed, microorganisms present in the sample are separated and aligned cell by cell in an optical analysis chamber by a flow-focusing method. This way, optical properties can be acquired at the single cell level allowing to take into account the intrinsic heterogeneity of the microbial population (heterogeneity has been observed even in a clonal population). In addition to the above mentioned advantages, a flow cytometry-based method can be automated in order to follow cell properties on-line during a process. It can also be applied to follow product quality during storage after downstream processing steps, such as freeze drying and spray drying (Volkert, 2008).

4.4. Authenticity

The authenticity of a probiotic culture is an important criterion to ensure the expected quality and thus predicted health-promoting effect of the probiotic product. Linked to strain authenticity is genetic stability, which reflects the susceptibility of the culture concerning genomic rearrangements in the course of its natural evolution. These rearrangements may reflect small variations introduced at specific or random positions of the genome through point mutations, deletions and insertions, but may also be linked to larger structural variations resulting from homologous recombination (vertical inheritance) and horizontal gene transfer events. Although this is a highly relevant issue in order to ensure that specific health-promoting characteristics and functionalities are not affected during long-term preservation and production, few studies have reported comprehensive data documenting the genetic stability of commonly used probiotic strains. Ideally, a rigorous assessment of a strain's genetic stability requires the availability of its whole-genome sequence. In the absence of this information, however, the use of molecular typing techniques probably provides the best estimate of genetic stability at the individual strain level.

A preliminary verification of bacterial strain authenticity can be obtained by partial 16S rRNA gene sequencing. If this analysis confirms the species identity of the probiotic culture, further characterization at strain level may be required. In **Chapter 2**, a series of typing methods is discussed which could be used for this purpose. However, as different typing methods offer different levels of genotypic resolution, the choice of the method and the appropriate protocol are crucial. As far as DNA fingerprinting approaches are concerned, AFLP analysis and PFGE of macrorestriction fragments offer the highest resolution at strain level (**Chapter 2**). These two methods are excellent tools for genotypic comparisons throughout the production or shelf-life period of a product. Sequence-based approaches such as the MLST schemes developed for several *Lactobacillus* and *Bifidobacterium* species are also relevant for typing of probiotic cultures, although their usefulness in strain authenticity matters still needs to be verified. Although not supported by producers and distributors of commercial probiotic products, deposit of probiotic cultures into an internationally recognized culture collection would provide an enduring source of reference material for confirmation of genetic stability.

Although it is generally assumed that *Lactobacillus* and *Bifidobacterium* strains used in probiotic applications show a high genotypic stability under different production conditions, more direct and in-depth evidence for this hypothesis is needed. Ideally, this should be done using a series of different molecular typing methods or, ultimately, comparative genomics. A number of genome projects have revealed that species used in probiotic products have specifically adapted themselves to specific environments. This is exemplified in the genomes of *Bifidobacterium longum* subsp. *longum* and *Bf. longum* subsp. *infantis* by the presence of many genes involved in the uptake and utilization of host-indigestible complex carbohydrates and polyols, supporting their genome adaptation to the human large intestine, where these are the predominant nutrient sources (Schell *et al.*, 2002; Lee & O'Sullivan, 2010). The genome of *Lactobacillus delbrueckii* subsp. *bulgaricus*, which is applied worldwide in yogurt production, is in a phase of rapid reductive evolution, as a possible result of its adaptation from a plant-associated habitat to a milk environment through the loss of superfluous functions and protocooperation with *S. thermophilus* (van de Guchte *et al.*, 2006). In the same way, comparative genomics could also determine the potential of probiotic strains to acquire and/or transfer DNA elements during host passage and long-term colonization, which is a research area that has remained virtually unexplored.

4.5. Labelling and claims

Official controls by national authorities are performed to ensure verification of compliance with food law. Apart from the risk of using unauthorized strains, product mislabelling is a known problem, partly because of the use of phenotyping or genotyping methods with a lack of discriminative power (Huys *et al.*, 2006). In addition to official controls, private controls by food-producing companies are important in the frame of protection of patented strains and industrial property rights.

In their "Guidelines for the Evaluation of Probiotics in Food" document, the FAO/WHO working group (FAO/WHO, 2002) recommends that the following information should be described on the label of probiotic products:

- genus, species and strain designation. Strain designation (definition) should not mislead consumers about the functionality of the strain;
- minimum viable numbers of each probiotic strain at the end of the shelf-life;
- the suggested serving size must deliver the effective dose of probiotics related to the health claim;
- health claim(s);
- proper storage conditions;
- corporate contact details for consumer information.

In most countries, only general health claims are currently allowed on foods containing probiotics. The FAO/WHO working group (FAO,WHO, 2002) recommended that specific health claims on foods be allowed relating to the use of probiotics, where sufficient scientific evidence is available. Such specific health claims should be permitted on the label and promotional material. For example, a specific claim that states that a probiotic “reduces the incidence and severity of rotavirus diarrhea in infants” would be more informative to the consumer than a general claim that states “improves gut health”. It is recommended that it has to be the responsibility of the product manufacturer that an independent third party review by scientific experts in the field be conducted to establish that health claims are truthful and not misleading.

In line with the suggestions of the FAO/WHO working group (FAO/WHO, 2002), on December 20, 2006, the European Parliament and the Council published a novel regulation (Regulation (EC) N°1924/2006) on “Nutrition and Health Claims Made on Foods” (<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1924R%2801%29:EN:NOT>). This regulation applies to all nutritional and health claims relating to all types of food intended for final consumers, thus also including probiotic products brought to the market with a health claim. The regulation aims to harmonise the nutrition and health claims at European level in order to better protect consumers, including commercial communications (labelling, presentation and promotional campaigns) and trade marks and other brand names which may be construed as nutrition or health claims. The regulation establishes the authorisation procedures required to ensure that claims on food labelling, presentation and advertising are clear, concise and based on evidence accepted by the whole scientific community.

5. REFERENCES

- Achtman M. Evolution, population structure, and phylogeography of genetically monomorphic bacterial pathogens. *Annual Reviews in Microbiology*. 2008;62:53-70.
- Antikainen J, Tarkka E, Haukka K, Siitonen A, Vaara M, Kirveskari J. New 16-plex PCR method for rapid detection of diarrheagenic *Escherichia coli* directly from stool samples. *Eur J Clin Microbiol Infect Dis* 2009;28(8):899-908.
- Adams MR, Marteau P. On the safety of lactic acid bacteria from food. *Int J Food Microbiol* 1995;27:263-4
- Araya-Kojima T, Yaeshima T, Ishibashi N, Shimamura S, Hayasawa H. Inhibitory effects of *Bifidobacterium longum* BB536 on harmful intestinal bacteria. *Bifidobacter Microflora* 1995;14:59-66.
- Araya-Kojima T, Yaeshima T, Ishibashi N, Shimamura S, Hayasawa H. Inhibitory effects of human-derived *Bifidobacterium* on pathogenic *Escherichia coli* serotype O-111. *Biosci Microflora* 1996;15:17-22.
- Baleiras Couto MM, Eijmsa B, Hofstra H, Huis in't Veld JH, van der Vossen JM. Evaluation of molecular typing techniques to assign genetic diversity among *Saccharomyces cerevisiae* strains. *Appl Environ Microbiol* 1996;62(1):41-6.
- Ben Amor K, Vaughan EE, de Vos WM. Advanced molecular tools for the identification of lactic acid bacteria. *J Nutr* 2007;137(3 Suppl 2):741S-7S.
- Bernardeau M, Guguen M, Vernoux JP. Beneficial lactobacilli in food and feed: long-term use, biodiversity and proposals for specific and realistic safety assessments. *FEMS Microbiol. Rev.* 2006;30:487-513.
- Berney M, Hames F, Bosshard F, Weilenmann H U, Egli T. Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLigth kit in combination with flow cytometry. *Applied and environmental microbiology*.2007;70(10):3283-90.
- Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. *Infect Immun* 1979;23:403-11.
- Berg RD. Inhibition of *Escherichia coli* translocation from the gastrointestinal tract by normal cecal flora in gnotobiotic or antibiotic-decontaminated mice. *Infect Immun* 1980;29:1073-81.
- Berg RD. Bacterial translocation from the gastrointestinal tracts of mice receiving immunosuppressive chemotherapeutic agents. *Curr Microbiol* 1983;285-92.
- Berg RD, Wommack E, Deitch EA. Immunosuppression and intestinal bacterial overgrowth synergistically promote bacterial translocation. *Arch Surg* 1988;123(11):1359-64.
- Berg RD. Translocation and the indigenous gut flora. In: Fuller R, editor. *Probiotics, the scientific basis*. London: Chapman & Hall, 1992:55-85
- Berg RD. Bacterial translocation from the gastrointestinal tract. *Adv. Exp. Med. Biol.* 1999;473:11-30.

Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;371(9613):651-9.

Bjarnason A, Adler SN, Bjarnason I. Probiotic prophylaxis in predicted severe acute pancreatitis. *Lancet* 2008;372(9633):114-5.

Booth I.R. Stress and the single cell : intrapopulation diversity is a mechanism to ensure survival upon exposure to stress. *International journal of food microbiology*.2002;78:19-30.

Breeuwer P. AT. Assessment of viability of microorganisms employing fluorescence techniques. *International journal of food microbiology*.2000;55:193-200.

Cai H, Rodriguez BT, Zhang W, Broadbent JR, Steele JL. Genotypic and phenotypic characterization of *Lactobacillus casei* strains isolated from different ecological niches suggests frequent recombination and niche specificity. *Microbiology* 2007;153(Pt 8):2655-65.

Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of *Lactobacillus*: a retrospective review of over 200 cases. *Eur J Clin Microbiol Infect Dis* 2005;24(1):31-40.

Champagne CP, Raymond Y, Gonthier J, Audet P. Enumeration of the contaminating bacterial microbiota in unfermented pasteurized milks enriched with probiotic bacteria. *Can J Microbiol* 2009;55(4):410-8.

Champagne CP, Raymond Y, Gonthier J, Audet P. Enumeration of the contaminating bacterial flora in unfermented pasteurised milks enriched with probiotic bacteria. *Canadian Journal of Microbiology / Revue Canadienne de Microbiologie*. 2009;55(4),p.410-18.

Chan JF, Lau SK, Woo PC, Fan RY, Ip JJ, Chan CF, et al. *Lactobacillus rhamnosus* hepatic abscess associated with Mirizzi syndrome: a case report and review of the literature. *Diagn Microbiol Infect Dis* 2010;66(1):94-7.

Charteris WP, Kelly PM, Morelli L, Collins JK. Antibiotic susceptibility of potentially probiotic *Lactobacillus* species. *J Food Prot* 1998a;61(12):1636-43.

Charteris WP, Kelly PM, Morelli L, Collins JK. Antibiotic susceptibility of potentially probiotic *Bifidobacterium* isolates from the human gastrointestinal tract. *Lett Appl Microbiol* 1998b;26(5):333-7.

Cheah PY. Hypotheses for the etiology of colorectal cancer — an overview. *Nutr Cancer* 1990;14:5–13

Chenoll E, Macian MC, Aznar R. Identification of *Carnobacterium*, *Lactobacillus*, *Leuconostoc* and *Pediococcus* by rDNA-based techniques. *Syst Appl Microbiol* 2003;26(4):546-56.

Cherif A, Brusetti L, Borin S, Rizzi A, Boudabous A, Khyami-Horani H, et al. Genetic relationship in the 'Bacillus cereus group' by rep-PCR fingerprinting and sequencing of a *Bacillus anthracis*-specific rep-PCR fragment. *J Appl Microbiol* 2003;94(6):1108-19.

Choi CH. Prophylactic effect of *Lactobacillus* GG in animal colitis and its effect on cytokine secretion and mucin gene expressions. *Korean J.Gastroenterol*. 2004;44:50-2.

Coeuret V, Gueguen M, Vernoux JP. Numbers and strains of lactobacilli in some probiotic products. *International Journal of Food Microbiology*. 2004;97:147-56

Coudeyras S, Marchandin H, Fajon C, Forestier C. Taxonomic and strain-specific identification of

- the probiotic strain *Lactobacillus rhamnosus* 35 within the *Lactobacillus casei* group. *Applied and Environmental Microbiology*. 2008;74:2679-89.
- Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. *Lactobacillus acidophilus* as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. *Digestion* 2006;73(2-3):107-10.
- Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics - *Saccharomyces boulardii*. *Alimentary Pharmacology & Therapy*. 2007;26:767-78.
- Daniel HM, Meyer W. Evaluation of ribosomal RNA and actin gene sequences for the identification of ascomycetous yeasts. *Int J Food Microbiol* 2003;86:61-78.
- Daniel C, Poiret S, Goudercourt D, Dennin V, Leyer G, Pot B. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. *Appl Environ Microbiol* 2006;72(9):5799-805.
- De Baets L, Van Iwaarden P, Meeus N, Schimmel H, Philipp W, Emons H. First certified reference materials for molecular fingerprinting of two approved probiotic *Bacillus* strains. *Int J Food Microbiol* 2009;129(1):16-20.
- De Bruyne K, Franz CM, Vancanneyt M, Schillinger U, Mozzi F, de Valdez GF, et al. *Pediococcus argentanicus* sp. nov. from Argentinean fermented wheat flour and identification of *Pediococcus* species by *pheS*, *rpoA* and *atpA* sequence analysis. *Int J Syst Evol Microbiol* 2008;58(Pt 12):2909-16.
- De Bruyne K, Schillinger U, Caroline L, Boehringer B, Cleenwerck I, Vancanneyt M, et al. *Leuconostoc holzapfelii* sp. nov., isolated from Ethiopian coffee fermentation and assessment of sequence analysis of housekeeping genes for delineation of *Leuconostoc* species. *Int J Syst Evol Microbiol* 2007;57(Pt 12):2952-9.
- Deitch EA, Maejima K, Berg RD. Effect of oral antibiotics and bacterial overgrowth on the translocation of the GI tract microflora in burned rats. *J Trauma* 1985;25:385-92.
- Deitch EA, Xu D, Lu Q, Berg RD. Bacterial translocation from the gut impairs systemic immunity. *Surgery* 1991;109:269-76.
- De Jonghe V, Coorevits A, De Block J, Van Coillie E, Grijspeerdt K, Herman L, et al. Toxinogenic and spoilage potential of aerobic spore-formers isolated from raw milk. *Int J Food Microbiol* 2010;136(3):318-25.
- Deitch EA, Hempa AC, Specian RD, Bery RD. A study of the relationships among survival gut origin, sepsis and bacterial translocation in a model of systemic inflammation. *J Trauma* 1992;32:141-7.
- de las Rivas B, Marcobal A, Muñoz R. Development of a multilocus sequence typing method for analysis of *Lactobacillus plantarum* strains. *Microbiology*. 2006;152:85-93.
- Delétoile A, Passet V, Aires J, Chambaud I, Butel MJ, Smokvina T, et al. Species delineation and clonal diversity in four *Bifidobacterium* species as revealed by multilocus sequencing. *Res Microbiol* 2010;161(2):82-90.
- Dherbécourt J, Thierry A, Madec MN, Lortal S. Comparison of amplified ribosomal DNA restriction analysis, peptidoglycan hydrolase and biochemical profiles for rapid dairy propionibacteria species identification. *Res Microbiol* 2006;157(10):905-13.

Diancourt L, Passet V, Chervaux C, Garault P, Smokvina T, Brisse S. Multilocus sequence typing of *Lactobacillus casei* reveals a clonal population structure with low levels of homologous recombination. *Appl Environ Microbiol* 2007;73(20):6601-11.

Doi A, Nakajo K, Kamiya T, Ohkusu K. Splenic abscess caused by *Lactobacillus paracasei*. *J Infect Chemother* 2011;17(1):122-5.

Domann E, Hain T, Ghai R, Billion A, Kuenne C, Zimmermann K, et al. Comparative genomic analysis for the presence of potential enterococcal virulence factors in the probiotic *Enterococcus faecalis* strain Symbioflor 1. *Int J Med Microbiol* 2007;297(7-8):533-9.

Donohue DC, Salminen S. Safety of probiotic bacteria. *Asia Pac J Clin Nutr* 1996;5:25–8.

Douglas CW, Brown PR, Preston FE. Platelet aggregation by oral streptococci. *FEMS Microbiol Lett* 1990;72:63–8.

Drasar BS, Hill MJ. Human intestinal flora. London: Academic Press, 1974;72–102.

Duc le H, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of *Bacillus* probiotics available for human use. *Appl Environ Microbiol* 2004;70(4):2161-71.

EFFCA - European Food and Feed Cultures Association. Definition of Microbial Food Culture (MFC), 2003.

EFSA – European Food Safety Authority. Updating of the criteria used in the assessment of bacteria for resistance to antibiotics of human or veterinary importance. Question No. EFSA-Q-2004-079. *The EFSA Journal* 2005; 223:1-12.

EFSA. - European Food Safety Authority. Scientific opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed. *EFSA Journal* 2009;7:1431

EFSA - European Food Safety Authority on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements of European Food Safety Authority or health claims related to gut and immune function. *EFSA Journal* 2011;9 (4):1984.

Enache-Angoulvant, A. and C. Hennequin. Invasive *Saccharomyces* infection: a comprehensive review. *Clin.Infect.Dis.* 2005;41:1559-68.

Ercolini D. PCR-DGGE fingerprinting: novel strategies for detection of microbes in food. *J Microbiol Methods.* 2004;56:297-314

EU – European Union. Regulation (EC) No. 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. *OJ L 404*, 30.12.2006, p. 9-25.

Internet: <http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:012:0003:0018:EN:PDF>

FAO-WHO. Food and Agriculture Organization – World Health Organization. Report on Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria 2001. Internet: <ftp://ftp.fao.org/docrep/fao/meeting/009/y6398e.pdf>

FAO/WHO. Food and Agriculture Organization – World Health Organization. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. 2002. Internet:<ftp://ftp.fao.org/es/esn/food/wgreport2.pdf>

FAO/WHO. Food and Agriculture Organization – World Health Organization. Probiotics in food: Health and nutritional properties and guidelines for evaluation. Food and Nutrition Paper 85. 2006. Internet:<ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf>

Fasoli S, Marzotto M, Rizzotti L, Rossi F, Dellaglio F, Torriani S. Bacterial composition of commercial probiotic products as evaluated by PCR-DGGE analysis. *Int J Food Microbiol* 2003;82(1):59-70.

Fell JW, Boekhout T, Fonseca A, Scorzetti G, Statzell-Tallman A. Biodiversity and systematics of basidiomycetous yeasts as determined by large-subunit rDNA D1/D2 domain sequence analysis. *Int J Syst Evol Microbiol* 2000;50 Pt 3:1351-71.

Ferrari A, Pacini N, Canzi E. A note on bile acid transformations by strains of *Bifidobacterium*. *J Appl Bacteriol* 1980;49:193–7

Foligne B, Dewulf J, Breton J, Claisse O, Lonvaud-Funel A, Pot B. Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by *Oenococcus oeni*. *Int J Food Microbiol* 2010;140(2-3):136-45.

Foligne B, Dewulf J, Vandekerckove P, Pignede G, Pot B. Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. *World J Gastroenterol* 2010;16(17):2134-45.

Foo MC, Lee A. Immunological response of mice to members of the autochthonous intestinal microflora. *Infect Immun* 1972;6:525–32.

Foulquié Moreno, M.R., Sarantinopoulos, P., Tsakalidou, E. & De Vuyst, L. (2006). The role and application of enterococci in food and health. *International Journal of Food Microbiology* **106**, 1-24.

Franz C.M.A.P., Huch M., Abriouel H., Holzapfel W. & Gálvez A. (2011). Enterococci as probiotics and their implications in food safety. *International Journal of Food Microbiology* 151:125-140.

Fuller R. Probiotics in man and animals. *J Appl Bacteriol* 1989;66:365–38.

Furet JP, Quenee P, Tailliez P. Molecular quantification of lactic acid bacteria in fermented milk products using real-time quantitative PCR. *Int J Food Microbiol* 2004;97(2):197-207.

Gevers D, Huys G, Swings J. Applicability of rep-PCR fingerprinting for identification of *Lactobacillus* species. *FEMS Microbiol Lett* 2001;205(1):31-6.

Gevers D, Huys G, Swings J. In vitro conjugal transfer of tetracycline resistance from *Lactobacillus* isolates to other Gram-positive bacteria. *FEMS Microbiol.Lett* 2003;225(1):125-30.

Gómez Zavaglia A, de Urraza P, De Antoni G. Characterization of *Bifidobacterium* strains using BOX primers. *Anaerobe* 2000;6:169-77.

Gomez JAL, Hendrickx APA, Willems RJ, Top J, Sava I, Huebner J, Witte W and Werner G. 2011. Intra- and interspecies genomic transfer of the *Enterococcus faecalis* pathogenicity island. *PLOS One* 6: e16720

Gonzalez SS, Barrio E, Gafner J, Querol A. Natural hybrids from *Saccharomyces cerevisiae*, *Saccharomyces bayanus* and *Saccharomyces kudriavzevii* in wine fermentations. *FEMS Yeast Res* 2006;6(8):1221-34.

Grand M, Küffer M, Baumgartner A. Quantitative analysis and molecular identification of bifidobacteria strains in probiotic milk products. *European Food Research and Technology*. 2003;217:90-2.

Groenewald, M., Daniel, H.M., Robert, V., Poot, G.A. & Smith, M.Th. (2008). Polyphasic re-examination of *Debaryomyces hansenii* strains and reinstatement of *D. Hansenii*, *D. Fabryi* and *D. Subglobosus*. *Persoonia* 21, 17-27.

Gronbach K, Eberle U, Muller M, Olschlager TA, Dobrindt U, Leithauser F, et al. Safety of probiotic *Escherichia coli* strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. *Infect Immun* 2010;78(7):3036-46.

Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, et al. Analysis of the genome structure of the nonpathogenic probiotic *Escherichia coli* strain Nissle 1917. *J Bacteriol* 2004;186(16):5432-41.

Guarner F, Schaafsma GJ. Probiotics. *Int J Food Microbiol*. 1998;39:237-8.

Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L. Should yoghurt cultures be considered probiotic? *Br J Nutr* 2005;93(6):783-6.

Gueimonde M, Ouwehand AC, Salminen S. Safety of Probiotics. *Scan J of Nutrition*.2004;48:42-8

Guenther KE, Straube E, Pfister W, Guenther A, Huebler A. Severe sepsis after probiotic treatment with *Escherichia coli* NISSLE 1917. *Pediatr.Infect.Dis.J*. 2010;29:188-9.

Hamilton-Miller JM, Shah S, Winkler JT. Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. *Public Health Nutr* 1999;2(2):223-9.

Hammad AM, Shimamoto T. Towards a compatible probiotic-antibiotic combination therapy: assessment of antimicrobial resistance in the Japanese probiotics. *J Appl Microbiol* 2010;109(4):1349-60.

Harty DWS, Patrikakis M, Hume EBH, Oakey HJ, Knox KW. The aggregation of human platelets by *Lactobacillus* species. *J Gen Appl Microbiol* 1993a;139:2945–51.

Harty DWS, Patrikakis M, Knox KW. Identification of *Lactobacillus* strains isolated with infective endocarditis and comparison of their surface-associated properties with those of other strains of the same species. *Microbiol Ecol Health Dis* 1993b;6:191–201.

Hata D, Yoshida A, Ohkubo H, Mochizuki Y, Hosoki Y, Tanaka R, et al. Meningitis caused by *Bifidobacterium* in an infant. *Pediatr Infect Dis J* 1988;7(9):669-71.

Havenaar R, Huis in't Veld JHJ. Probiotics: A general view. In: Wood BJB: *The Lactic Acid Bacteria*, Vol. 1: *The Lactic Acid Bacteria in Health and Disease*, Chapman & Hall, New York, NY.1992;209–224.

Helgason E, Tourasse NJ, Meisal R, Caugant DA, Kolsto AB. Multilocus sequence typing scheme for bacteria of the *Bacillus cereus* group. *Appl Environ Microbiol* 2004;70(1):191-201.

Holzappel WH, Haberer P, Snel J, Schillinger U, Huis in't Veld JH. Overview of gut flora and probiotics. *Int J Food Microbiol* 1998;41(2):85-101.

- Holzappel WH, Haberer P, Geisen R, Bjorkroth J, Schillinger U. Taxonomy and important features of probiotic microorganisms in food and nutrition. *Am J Clin Nutr* 2001;73(2 Suppl):365S-73S.
- Homan WL, Tribe D, Poznanski S, Li M, Hogg G, Spalburg E, et al. Multilocus sequence typing scheme for *Enterococcus faecium*. *J Clin Microbiol* 2002;40(6):1963-71.
- Hong HA, Duc le H, Cutting SM. The use of bacterial spore formers as probiotics. *FEMS Microbiol Rev* 2005;29(4):813-35.
- Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. *Gut Liver* 2009;3(2):101-7.
- Hutt P, Koll P, Stsepetova J, Alvarez B, Mandar R, Krogh-Andersen K, et al. Safety and persistence of orally administered human *Lactobacillus* sp. strains in healthy adults. *Benef Microbes* 2011;2(1):79-90.
- Huys G, D'Haene K, Swings J. Genetic basis of tetracycline and minocycline resistance in the potentially probiotic *Lactobacillus plantarum* strain CCUG 43738. *Antimicrobial Agents and Chemotherapy* 2006;50:1550-1.
- Huys G, Vancanneyt M, D'Haene K, Vankerckhoven V, Goossens H, Swings J. Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. *Research in Microbiology*. 2006;157:803-10.
- Huys G, Vanhoutte T, Vandamme P. Application of sequence-dependent electrophoresis fingerprinting in exploring biodiversity and population dynamics of human intestinal microbiota: what can be revealed? *Interdiscip Perspect Infect Dis* 2008;2008:597603.
- Huys G, D'Haene K, Cnockaert M, Tosi L, Danielsen M, Florez AB, et al. Intra- and interlaboratory performances of two commercial antimicrobial susceptibility testing methods for bifidobacteria and nonenterococcal lactic acid bacteria. *Antimicrob Agents Chemother* 2010;54(6):2567-74.
- ILSI - The International Life Sciences Institute. Concepts of functional foods 2002.
- Ishibashi N, Yamazaki S. Probiotics and safety. *Am J Clin Nutr* 2001;73(2 Suppl):465S-70S.
- Jacobsen L, Wilcks A, Hammer K, Huys G, Gevers D, Andersen SR. Horizontal transfer of *tet(M)* and *erm(B)* resistance plasmids from food strains of *Lactobacillus plantarum* to *Enterococcus faecalis* JH2-2 in the gastrointestinal tract of gnotobiotic rats. *FEMS Microbiol.Ecol.* 2007;59(1),158-66.
- Jacobi CA, Schulz C, Malfertheiner P. Treating critically ill patients with probiotics: Beneficial or dangerous? *Gut Pathog* 2011;3(1):2.
- Jett BD, Huycke MM, Gilmore MS. Virulence of enterococci. *Clin Microbiol Rev* 1994;462-78.
- Johnson, AP. The pathogenicity of enterococci. *J.Antimicrob.Chemother* 1994;33:1083-9.
- Joosten H, Bidlas E, Garofalo N. Salmonella detection in probiotic products. *Int J Food Microbiol* 2006;110(1):104-7.
- Kastner S, Perreten V, Bleuler H, Hugenschmidt G, Lacroix C, Meile L. Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food. *Syst Appl Microbiol* 2006;29(2):145-55.

- Kim BJ, Kim HY, Yun YJ, Kook YH. Differentiation of *Bifidobacterium* species using partial RNA polymerase {beta}-subunit (*rpoB*) gene sequences. *Int J Syst Evol Microbiol* 2010;60(Pt 12):2697-704.
- Klare I, Konstabel C, Muller-Bertling S, Reissbrodt R, Huys G, Vancanneyt M, et al. Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria. *Appl Environ Microbiol* 2005;71(12):8982-6.
- Klare I, Konstabel C, Werner G, Huys G, Vankerckhoven V, Kahlmeter G, et al. Antimicrobial susceptibilities of *Lactobacillus*, *Pediococcus* and *Lactococcus* human isolates and cultures intended for probiotic or nutritional use. *J Antimicrob Chemother* 2007;59(5):900-12.
- Klein G, Pack A, Bonaparte C, Reuter G. Taxonomy and physiology of probiotic lactic acid bacteria. *Int J Food Microbiol* 1998;41(2):103-25.
- Klein VG, Bonaparte C, Reuter G. Lactobazillen als Starterkulturen für die Milchwirtschaft unter dem Gesichtspunkt der Sicheren Biotechnologie. (*Lactobacilli* as starter cultures for the dairy industry with respect to safe biotechnology.) *Milchwissenschaft* 1992;47:632–6.
- Korhonen, JM, Danielsen M, Mayo B, Egervärn M, Axelsson L, Huys G, et al. Antimicrobial susceptibility and proposed microbiological cut-off values of lactobacilli by phenotypic determination. *Int J of Probiotics and Prebiotics*. 2008;3:257-68
- Křížová J, Španová A, Rittich B.. Evaluation of amplified ribosomal DNA restriction analysis (ARDRA) and species-specific PCR for identification of *Bifidobacterium* species. *Systematic and Applied Microbiology*. 2006;29:36-44.
- Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004;53(11):1617-23.
- Lampkowska J, Feld L, Monaghan A, Toomey N, Schjorring S, Jacobsen B, et al. A standardized conjugation protocol to asses antibiotic resistance transfer between lactococcal species. *Int J Food Microbiol* 2008;127(1-2):172-5.
- Lau SK, Woo PC, Fung AM, Chan KM, Woo GK, Yuen KY. Anaerobic, non-sporulating, Gram-positive bacilli bacteraemia characterized by 16S rRNA gene sequencing. *J Med Microbiol* 2004;53(Pt 12):1247-53.
- Laverde Gomez JA, Hendrickx AP, Willems RJ, Top J, Sava I, Huebner J, et al. Intra- and interspecies genomic transfer of the *Enterococcus faecalis* pathogenicity island. *PLoS One* 2011;6(4):e16720
- Lee JH, O'Sullivan DJ. Genomic insights into bifidobacteria. *Microbiology And Molecular Biology Reviews* 2010;74:378-416
- Leroy, F. & De Vuyst, L. (2004). Functional lactic acid bacteria starter cultures for the food fermentation industry. *Trends in Food Science and Technology* **15**, 67-78.
- Lieckfeldt E, Meyer W, Börner T. Rapid identification and differentiation of yeasts by DNA and PCR fingerprinting. *Journal of Basic Microbiology*. 1993;33:413-426.
- Lilly DM, Stillwell RH. Probiotics: Growth promoting factors produced by microorganisms. *Science* 1965;147:747-8.

- Lowder M, Unge A, Maraha N, Jansson JK, Swiggett J, Oliver JD. Effect of starvation and the viable but nonculturable state on green fluorescent protein (GFP) fluorescence in GFP-tagged *Pseudomonas fluorescens* A506. *Applied and environmental microbiology*.2000;66(8):3160-5.
- MacFie J, O'Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis, a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. *Gut*. 1999;45(2):223-8.
- Mackay A D, Taylor MB, Kibbler CC, Hamilton-Miller JM. *Lactobacillus* endocarditis caused by a probiotic organism. *Clin. Microbiol. Infect.* 1999;5:290-2.
- Maejima K, Tajima Y. Association of gnotobiotic mice with various organisms isolated from conventional mice. *Jpn J Exp Med* 1973;43: 289–96.
- Manan NA, Chin Chin S, Abdullah N, Wan HY. Differentiation of *Lactobacillus*-probiotic strains by visual comparison of random amplified polymorphic DNA (RAPD) profiles. *African J of Biotechnology* 2009;8:3964-9.
- Masco L, Huys G, Gevers D, Verbruggen L, Swings J. Identification of *Bifidobacterium* species using rep-PCR fingerprinting. *Systematic and Applied Microbiology* 2003;26:557-63.
- Masco L, Huys G, De Brandt E, Temmerman R, Swings J. Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. *Intern J of Food Microbiol* 2005;102:221-30.
- Masco L, Van Hoorde K, De Brandt E, Swings J, Huys G. Antimicrobial susceptibility of *Bifidobacterium* strains from humans, animals and probiotic products. *J Antimicrob Chemother* 2006;58(1):85-94.
- Masco L, Temmerman R, Vanhoutte T, Swings J, Huys G. Quantification of bifidobacteria in probiotic products by real-time PCR targeting the 16S rRNA and *recA* genes. *Intern J of Food Microbiol* 2007;113:351-7
- Mättö J, Van Hoek AHAM, Domig KJ, Saarela M, Belén Floréz A, Brockmann E, et al. Susceptibility of human and probiotic *Bifidobacterium* spp. to selected antibiotics as determined by the Etest method. *Int Dairy J* 2007;17:1123-31.
- Meile L, Le Blay G, Thierry A. Safety assessment of dairy microorganisms: *Propionibacterium* and *Bifidobacterium*. *Int. J. Food Microbiol.* 2008;126:316-20.
- Metchnikoff E. Lactic acid as inhibiting intestinal putrefaction. In: Heinemann W, editor. *The prolongation of life: Optimistic studies*. London 1907. P. 61-183.
- Midtvedt T, Norman A. Bile acid transformation by microbial strains belonging to genera found in intestinal contents. *Acta Pathol Microbiol Scand* 1967;7:629–38.
- Mitterdorfer G, Mayer HK, Kneifel W, Viernstein H. Clustering of *Saccharomyces boulardii* strains within the species *S. cerevisiae* using molecular typing techniques. *J Appl Microbiol* 2002;93(4):521-30.
- Moreira JL, Mota RM, Horta MF, Teixeira SM, Neumann E, Nicoli JR, et al. Identification to the species level of *Lactobacillus* isolated in probiotic prospecting studies of human, animal or food origin by 16S-23S rRNA restriction profiling. *BMC Microbiol* 2005;5:15.

- Müller S, Nebe-von-Caron G. Functional single-cell analyses : flow cytometry and cell sorting of microbial populations and communities. *FEMS microbiology reviews*.2010;34:554-87.
- Muñoz R, Gomez A, Robles V, Rodriguez P, Cebollero E, Tabera L, et al. Multilocus sequence typing of oenological *Saccharomyces cerevisiae* strains. *Food Microbiol* 2009;26(8):841-6.
- Naser SM, Thompson FL, Hoste B, Gevers D, Dawyndt P, Vancanneyt M, et al. Application of multilocus sequence analysis (MLSA) for rapid identification of *Enterococcus* species based on *rpoA* and *pheS* genes. *Microbiology* 2005;151(Pt 7):2141-50.
- Naser SM, Dawyndt P, Hoste B, Gevers D, Vandemeulebroecke K, Cleenwerck I, et al. Identification of lactobacilli by *pheS* and *rpoA* gene sequence analyses. *Int J Syst Evol Microbiol* 2007;57(Pt 12):2777-89.
- Nataro JP, Kaper JB. Diarrheagenic *Escherichia coli*. *Clin Microbiol Rev* 1998;11(1):142-201.
- Oakey HJ, Harty DWS, Knox KW. Enzyme production by lactobacilli and the potential link with infective endocarditis. *J Appl Bacteriol* 1995;78:142-8
- Ouwehand AC, Vesterlund S. Health aspects of probiotics. *IDrugs* 2003;6:573-80.
- Palmisano MM, Nakamura LK, Duncan KE, Istock CA, Cohan FM. *Bacillus sonorensis* sp. nov., a close relative of *Bacillus licheniformis*, isolated from soil in the Sonoran Desert, Arizona. *Int J Syst Evol Microbiol* 2001;51(Pt 5):1671-9.
- Posteraro B, Sanguinetti M, Romano L, Torelli R, Novarese L, Fadda G. Molecular tools for differentiating probiotic and clinical strains of *Saccharomyces cerevisiae*. *Int J Food Microbiol* 2005;103(3):295-304.
- Raftis EJ, Salvetti E, Torriani S, Felis GE, O'Toole PW. Genomic diversity of *Lactobacillus salivarius*. *Appl Environ Microbiol* 2011;77(3):954-65.
- Ratna Sudha M, Chauhan P, Dixit K, Babu S, Jamil K. Molecular typing and probiotic attributes of a new strain of *Bacillus coagulans* – Unique IS-2: a potential biotherapeutic agent. *Genetic Engineering and Biotechnology J* 2010.
- Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. Liver abscess due to a *Lactobacillus rhamnosus* strain indistinguishable from *L. rhamnosus* strain GG. *Clinical Infectious Diseases* 1999;28:1159-60.
- Reuter G. Present and future of probiotics in Germany and in Central Europe. *Bioscience and Microflora* 1997;16:43-51.
- Roy D, Ward P, Champagne G. Differentiation of bifidobacteria by use of pulsed-field gel electrophoresis and polymerase chain reaction. *Int J of Food Microbiol* 1996;29:11-29.
- Roy D, Sirois S. Molecular differentiation of *Bifidobacterium* species with amplified ribosomal DNA restriction analysis and alignment of short regions of the *ldh* gene. *FEMS Microbiology Letters*.2000;191:17-24.
- Roy D. Media for the isolation and enumeration of bifidobacteria in dairy products. *Int J of Food Microbiol*. 2001;69:167-82

Ruseler-Van Embden GH, Van Lieshout LMC, Gosselink MJ, Marteau P. Inability of *Lactobacillus casei* strain GG, *L. acidophilus*, and *Bifidobacterium bifidum* to degrade intestinal mucus glycoproteins. Scand J Gastroenterol 1995;30:675–80.

Salminen S, Marteau P. Safety of probiotic lactic acid bacteria and other probiotics. Lactic 97 (Proceedings). Adria Normandie Caen, 1997:71–2.

Salminen S, Von Wright A, Morell L, Marteau P, Brassart D, De Vos W et al. Demonstration of safety of probiotics - a review. Int J of Food Microbiol 1998;44:93-106.

Salminen S, von Wright AJ, Ouwehand AC, Holzapfel WH. Safety assessment of probiotics and starters. In: Adams MR, Nout MJR, editors. Fermentation and food safety, 1st ed. Gaithersburg, MD. Aspen; 2001. p. 239-51.

Salminen MK, Tynkkynen H, Rautelin M, Saxelin M, Vaara P, Ruutu S et al. *Lactobacillus* bacteremia during a rapid increase in probiotic use of *Lactobacillus rhamnosus* GG in Finland. Clinical Infectious Diseases 2002;35:1155-60.

Sanders ME, Morelli L, Tompkins TA. Sporeformers as human probiotics: *Bacillus*, *Sporolactobacillus*, and *Brevibacillus*. Comprehensive Reviews in Food Science and Food Safety 2003;2:101-10.

Sanders ME. Probiotics: considerations for human health. Nutr.Rev 2003;61:91-9.

Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach J, Hörmannspurger G et al. Safety assessment of probiotics for human use. Gut Microbes 2010;1:1-22.

Saxelin M. *Lactobacillus* GG - a human probiotic strain with thorough clinical documentation Food Rev Int 1997;13: 293-313.

Saxelin M, Chuang NH, Chassy B, Rautelin H, Makela PH, Salminen S et al. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin.Infect.Dis 1996;22:564-66.

Schell MA., Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G et al. The genome sequence of *Bifidobacterium longum* reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci USA 2002; 99:14422-7.

Schillinger U. Isolation and identification of lactobacilli from novel-type probiotic and mild yoghurts and their stability during refrigerated storage. Int J of Food Microbiol 1999;47:79-87.

Scorzetti G, Fell JW, Fonseca A, Statzell-Tallman A. Systematics of basidiomycetous yeasts: a comparison of large subunit D1/D2 and internal transcribed spacer rDNA regions. FEMS Yeast Research 2002;2:495-517.

Sedman PC, Macfie J, Sager P, Mitchell C, May J, Mancey-Jones B et al. The prevalence of gut translocation in humans. Gastroenterology 1994;107:643–9

Senesi SF, Celandroni A, Tavanti A, Ghelardi E. Molecular characterization and identification of *Bacillus clausii* strains marketed for use in oral bacteriotherapy. Applied and Environmental Microbiology 2001;67:834-39.

SHC – Belgian Superior Health Council. Risk profile of the *Bacillus cereus* group implicated in food poisoning. Rajkovic A, Uyttendaele M, Dierick K, Samapundo S, Botteldoorn N., Mahillon J, et al. Brussel:SHC; 2009. Advisory report 8316.

Steinberg SM. Bacterial translocation: what it is and what it is not. Am. J. Surg 2003;186:301–5.

Švec P, Vancanneyt M, Seman C, Snauwaert K, Lefebvre I, Sedlaceka et al. Evaluation of (GTG)₅-PCR for identification of *Enterococcus* spp. FEMS Microbiology Letters 2005;247:59-63.

Takahashi T, Morotomi M. Absence of cholic acid 7-dehydroxylase activity in the strains of *Lactobacillus* and *Bifidobacterium*. J Dairy Sci 1994;77:3275-86.

Temmerman R, Pot B, Huys G, Swings J. Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int J of Food Microbiol 2003a;81:1-10.

Temmerman, R, Scheirlinck I, Huys G, Swings J. Culture-independent analysis of probiotic products by denaturing gradient gel electrophoresis. Applied and Environmental Microbiology 2003b;69:220-6.

Teuber M, Meile L, Schwarz F. Acquired antibiotic resistance in lactic acid bacteria from food. Antonie van Leeuwenhoek 1999;76(1-4):115-37.

Theunissen J, Britz TJ, Torriani S, Witthuhn RC. Identification of probiotic microorganisms in South African products using PCR-based DGGE analysis. Int J of Food Microbiol 2005;98:11-21.

Threlfall E, Ward L, Frost J, Willshaw G. The emergence and spread of antibiotic resistance in food-borne bacteria. Int J of Food Microbiol 2000;62:1-5.

Tilsala-Timisjarvi A, Alatossava T. Characterization of the 16S-23S and 23S-5S rRNA intergenic spacer regions of dairy propionibacteria and their identification with species-specific primers by PCR. Int J Food Microbiol 2001;68(1-2):45-52.

Tissier H. Traitement des infections intestinales par la méthode de la flore bactérienne de l'intestin. CR.Soc Biol 1906;60:359-61.

Torriani S, Clementi F, Vancanneyt M, Hoste B, Dellaglio F, Kersters K. Differentiation of *Lactobacillus plantarum*, *L. pentosus* and *L. paraplantarum* species by RAPD-PCR and AFLP. Syst Appl Microbiol 2001;24(4):554-60.

Vancanneyt M, Huys G, Lefebvre K, Vankerckhoven V, Goossens H, Swings J. Intraspecific genotypic characterization of *Lactobacillus rhamnosus* strains intended for probiotic use and isolates of human origin. Syst Appl Microbiol 2006; 2:5376-83

Vancanneyt, M., Lombardi, A., Andrighetto, C., Knijff, E., Torriani, S., Björkroth, K.J., Franz, C.M.A.P., Foulquié Moreno, M.R., Revets, H., De Vuyst, L., Swings, J., Kersters, K., Dellaglio, F. & Holzapfel, W.H. (2002). Intra-species genomic groups in *Enterococcus faecium* and their correlation with origin and pathogenicity. *Applied and Environmental Microbiology* **68**, 1351-1359.

van de Guchte M, Penaud S, Grimaldi C, Barbe V, Bryson K, Nicolas P, et al. The complete genome sequence of *Lactobacillus bulgaricus* reveals extensive and ongoing reductive evolution. Proc Natl Acad Sci U S A 2006;103(24):9274-9.

van Hoek AHAM, Margolles A, Domig KJ, Korhonen JM, Zycka-Krzesinska J, Bardowski Jk et al. Molecular assessment of erythromycin and tetracycline resistance genes in lactic acid bacteria and bifidobacteria and their relation to the phenotypic resistance. Int J Probiotics Prebiotics 2008;3:271-80.

Vankerckhoven, V., G. Huys, M. Vancanneyt, C. Snauwaert, J. Swings, I. Klare, W. Witte, A. T. Van, S. Chapelle, C. Lammens, and H. Goossens. Genotypic diversity, antimicrobial resistance,

and virulence factors of human isolates and probiotic cultures constituting two intraspecific groups of *Enterococcus faecium* isolates. Appl. Environ. Microbiol. 2008a;74:4247-55.

Vankerckhoven V, Huys G, Vancanneyt M, Vael C, Klare I, Romond MB et al. Biosafety assessment of probiotics used for human consumption: Recommendations from the EU-PROSAFE project. Trends in Food Science and Technology 2008b;19:102-14.

Vassart, G., Georges, M., Monsieur, R., Brogas, H., Lequarre, A.S. & Christophe, D. (1987). A sequence in M13 phage detects hypervariable minisatellites in human and animal DNA. Science 235, 683-684.

Vejborg RM, Friis C, Hancock V, Schembri MA, Klemm P. A virulent parent with probiotic progeny: comparative genomics of *Escherichia coli* strains CFT073, Nissle 1917 and ABU 83972. Molecular Genetics and Genomics 2010;283:469-84.

Ventura M, Elli M, Reniero R, Zink R. Molecular microbial analysis of *Bifidobacterium* isolates from different environments by the species-specific amplified ribosomal DNA restriction analysis (ARDRA). FEMS Microbiol Ecol 2001;36(2-3):113-21.

Ventura M, Meylan V, Zink R. Identification and tracing of *Bifidobacterium* species by use of enterobacterial repetitive intergenic consensus sequences. Appl Environ Microbiol 2003;69:4296-301.

Ventura M, Canchaya C, Del Casale A, Dellaglio F, Neviani E, Fitzgerald GF, et al. Analysis of bifidobacterial evolution using a multilocus approach. Int J Syst Evol Microbiol 2006;56(Pt 12):2783-92.

Venugopalan, V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg. Infect. Dis 2010;16:1661-5.

Vitali B, Candela M, Matteuzzi D, Brigidi P. Quantitative detection of probiotic *Bifidobacterium* strains in bacterial mixtures by using real-time PCR. Syst Appl Microbiol 2003;26(2):269-76.

Volkert M, Ananta E, Luscher C, Knorr D. Effect of air freezing, spray freezing and pressure shift freezing on membrane integrity and viability of *Lactobacillus rhamnosus* GG. Journal of food engineering. 2008;87:532-540.

Wang LT, Lee FL, Tai CJ, Kasai H. Comparison of *gyrB* gene sequences, 16S rRNA gene sequences and DNA-DNA hybridization in the *Bacillus subtilis* group. Int J Syst Evol Microbiol 2007;57(Pt 8):1846-50.

Wang X, Andersson R, Soltesz V, Leveau P, Ihse I. Gut origin sepsis, macrophage function, and oxygen extraction associated with acute pancreatitis in the rat. World J Surg 1996;20(3):299-307; discussion -8.

Ward P, Roy D. Review of molecular methods for identification, characterization and detection of bifidobacteria. Lait 2005;85 :23-32.

Wehrle E, Moravek M, Dietrich R, Bürk C, Didier A, Märtlbauer E. Comparison of multiplex PCR, enzyme immunoassay and cell culture methods for the detection of enterotoxinogenic *Bacillus cereus*. J Microbiol Methods 2009;78(3):265-70.

Wells CL, Barton RG, Wavattne S, Dunn DL, Cerra FB. Intestinal bacterial flora, intestinal pathology, and lipopolysaccharide-induced translocation of intestinal bacteria. Circ Shock 1992;37:117-23.

Wessels, S., Axelsson, L., Hansen, E.B., De Vuyst, L., Laulund, S., Lähteenmäki, L., Lindgren, S., Mollet, B., Salminen, S., & von Wright, A. (2004). The lactic acid bacteria, the food chain, and their regulation. *Trends in Food Science and Technology* **15**, 498-505.

Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. *Am. J. Clin. Nutr* 2010;91:687-703.

Wind RD, Tolboom H, Klare I, Huys G, Knol J. Tolerance and safety of the potentially probiotic strain *Lactobacillus rhamnosus* PRSF-L477: a randomized, double-blind placebo-controlled trial in healthy volunteers. *Br J Nutr* 2010;104:1806-16.

Yeung PS, Sanders ME, Kitts CL, Cano R, Tong PS. Species-specific identification of commercial probiotic strains. *J Dairy Sci* 2002;85(5):1039-51.

Zhu L, Li W, Dong X. Species identification of genus *Bifidobacterium* based on partial HSP60 gene sequences and proposal of *Bifidobacterium thermacidophilum* subsp. *porcinum* subsp. nov. *Int J Syst Evol Microbiol* 2003;53(Pt 5):1619-23.

6. COMPOSITION OF THE WORKING GROUP

All experts joined the working group *in a private capacity*. The names of the members and experts of the Superior Health Council are indicated with an asterisk*.

The following experts were involved in drawing up the advice:

BOTTELDOORN Nadine	Food Microbiology	WIP-ISP
DAUBE Georges*	Food Microbiology	ULg
DELZENNE Nathalie*	Nutrition and Toxicology	UCL
DELVIGNE Frank	Industrial Microbiology and Biotechnology	ULg, CWBI
DIERICK Katelijne	Food Microbiology	ISP-WIV
DE VUYST Luc	Industrial Microbiology and Food Biotechnology	Vrije Universiteit Brussel
HEYNDRICKX Marc*	Food Microbiology	ILVO
HUYS Geert	Food Microbiology, Intestinal and Aquaculture Microbiology	UGent
POT Bruno	Microbiology and Hygiene, Infection and Immunity	Vrije Universiteit Brussel, Applied maths & Inst. Pasteur de Lille
THONART Philippe	Biochemistry and Industrial Microbiology	ULg, CWBI
VAEL Carl	Internal Medicine, Clinical Biology	KLINA Brasschaat
VANDENPLAS Yvan*	Gastroenterology, hepatology and nutrition	UZ Brussel
VAN GOSSUM André	Gastroenterology	ULB
VEEREMAN Geneviève	Pediatric Gastroenterology & Nutrition	UZ Brussel
VAN DE WIEL Tom	Microbial Ecology and Technology	UGent

The administration was represented by Isabel DE BOOSERE.

The working group was chaired by Nathalie DELZENNE and Georges DAUBE, the scientific secretary was Jean-Jacques DUBOIS.

Au sujet du Conseil Supérieur de la Santé (CSS)

Le Conseil Supérieur de la Santé est un organe d'avis fédéral dont le secrétariat est assuré par le Service Fédéral Santé publique, Sécurité de la Chaîne alimentaire et Environnement. Il a été fondé en 1849 et rend des avis scientifiques relatifs à la santé publique aux ministres de la Santé publique et de l'Environnement, à leurs administrations et à quelques agences. Ces avis sont émis sur demande ou d'initiative. Le CSS s'efforce d'indiquer aux décideurs politiques la voie à suivre en matière de santé publique sur base des connaissances scientifiques les plus récentes.

Outre son secrétariat interne composé d'environ 25 collaborateurs, le Conseil fait appel à un large réseau de plus de 500 experts (professeurs d'université, collaborateurs d'institutions scientifiques, acteurs de terrain, etc.), parmi lesquels 300 sont nommés par arrêté royal au titre d'expert du Conseil. Les experts se réunissent au sein de groupes de travail pluridisciplinaires afin d'élaborer les avis.

En tant qu'organe officiel, le Conseil Supérieur de la Santé estime fondamental de garantir la neutralité et l'impartialité des avis scientifiques qu'il délivre. A cette fin, il s'est doté d'une structure, de règles et de procédures permettant de répondre efficacement à ces besoins et ce, à chaque étape du cheminement des avis. Les étapes clé dans cette matière sont l'analyse préalable de la demande, la désignation des experts au sein des groupes de travail, l'application d'un système de gestion des conflits d'intérêts potentiels (reposant sur des déclarations d'intérêt, un examen des conflits possibles, et une Commission de Déontologie) et la validation finale des avis par le Collège (organe décisionnel du CSS, constitué de 40 membres issus du pool des experts nommés). Cet ensemble cohérent doit permettre la délivrance d'avis basés sur l'expertise scientifique la plus pointue disponible et ce, dans la plus grande impartialité possible.

Après validation par le Collège, les avis sont transmis au requérant et au ministre de la Santé publique et sont rendus publics sur le site internet (www.css-hgr.be). Un certain nombre d'entre eux sont en outre communiqués à la presse et aux groupes cibles concernés (professionnels du secteur des soins de santé, universités, monde politique, associations de consommateurs, etc.).

Si vous souhaitez rester informé des activités et publications du CSS, vous pouvez envoyer un mail à l'adresse suivante : info.hgr-css@health.belgium.be.